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‘Glioblastoma multiforme’ retains its reputation as the most common 
and devastating primary brain tumour affecting adults. This disease’s 
therapeutic resistance fortify it as one of the most challenging cancers to 
manage. Despite the implementation of aggressive treatment which consists of 
maximal safe surgical resection, followed by concomitant chemotherapy and 
high-dose radiation, the overall prognosis remains abysmal. Tumour 
recurrence is an inevitable event. At this stage, the identification of surviving 
cells responsible for tumour recurrence has yet to be clinically determined. 
Based on these observations, we hypothesized that there are different cell 
populations within glioblastoma that possess innate resistance mechanisms 
against chemo-radiation induced cell death, allowing them to survive and 
initiate tumour recurrence. 
 
For this project, we used an in vitro approach to explore key concepts 
underlying its notorious therapeutic resistance: tumour cell heterogeneity, the 
significance of MGMT (O6-methylguanine–DNA methyltransferase) in 
glioblastoma and the properties of a glioma stem cell population. . Here, the 
human glioblastoma cell line, LN229 was cultured to generate differentially-
derived cell populations that are postulated to contribute to therapeutic 
resistance: ‘temozolomide-resistant’ lines that express MGMT and glioma 
‘stem cell-like’ lines. These cells were characterized for their tumorigeneity 
and resistance to cell death, and found to be more resilient in comparison to 
the LN229 parent cells. In addition, they were also subjected to clinically 
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relevant doses of temozolomide (TMZ) and, or radiation therapy (RT); in 
order to simulate what is used in the clinical setting. Our results found that a 
subpopulation of LN229 ‘glioma stem cell-like’ cells was able to survive 
patient-relevant treatment. Hence, in order to explore these viable cells at a 
more in-depth level, their miRNA profiles were examined. We noted that there 
were miRNA clusters that demonstrated distinct changes in the presence of 
treatment. Subsequently, 3 selected miRNAs, miR-125a-3p, miR-629-p and 
miR-19b-3p were found to have significant downregulation in all 3 arms of 
treatment: TMZ only, RT only and combinatorial TMZ and RT. The miRNAs 
were functionally validated using miRNA mimics in LN229 ‘glioma stem cell-
like’ cells. Independent overexpression of these miRNAs demnonstrated 
reduced cell viability when the transfected cells were subjected to treatment. 
Following this, these 2 miRNAs were mapped to potential mRNA targets 
using a prediction programme. The mRNA targets RFX1 and FLVCR2 were 
found to be correspondingly upregulated in the presence of these 
downregulated miRNAs. RFX1 and FLVCR2 were functionally validated 
using a siRNA knockdown experiment, where they showed reduced cell 
viability when the transfected cells were subjected to treatment. This was in 
concordance with our miRNA data. Most significantly, our validated mRNA 
targets were found to stratify survival in patient glioma databases, 
REMBRANDT and Gravendeel. Putting it all together, our findings suggest 
that miRNAs have strong potentiality to be used as tools to seek for 
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‘I have made my peace with God. And I am ready to go’ 
A glioblastoma patient, Singapore 















1.1 Disease of interest: glioblastoma multiforme 
Introduction 
Gliomas belong to the group of primary brain tumours derived from 
the white matter cells of the central nervous system (CNS). These include glia 
cells, such as astrocytes and oligodendrocytes1. The gliomas are classified 
according to the criteria defined in the International Classification (IC) by the 
World Health Organization (WHO) in 20072,3. This classification is currently 
based on histopathological features, including morphological evaluation of 
neoplastic cells by defined criteria such as cell density, nuclear polymorphism, 
mitoses, infiltrative pattern, vascular proliferation and, or necrosis. These 
criteria concur in identifying malignancy grades of glial-based tumours based 
on biological features and growth patterns3,4. Under this classification, 
glioblastoma multiforme (GBM) is the most common and unfortunately, the 
most malignant5. Globally, GBM accounts for approximately 1% of all adult 
malignancies6, and is currently the most common primary CNS tumour 
affecting the adult population. 
 
General overview 
I. Risk Factors 
 At present, the aetiology of GBM is not fully ascertained. From a 
clinical perspective, it is difficult to tell individual patients the exact cause of 
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their tumours, especially because there are no common risk factors7. However, 
general consensus amongst experts in the field is that GBM is likely 
multifactorial, with genetic and environmental agents proposed as probable 
risk factors7. Unlike several other types of cancers, up to date, there remains 
no established pattern of the disease’s risk factors and, or target population. 
Family history of GBM may be rare. but when present, members are 
associated with a two-fold increase in the risk of developing glioma8. 
However, these cases are often seen in inherited tumour syndromes such as 
Turcot and Li-Fraumeni syndromes, neurofibromatosis type 1 and multiple 
enchondromatosis9-11. In these patients, the risk of other types of neoplasms 
are also apparent, indicating their genetic susceptibility is not exclusive to 
GBM alone. Furthermore, although genome-wide association studies did 
identify some susceptibility variants such as 20q13.33 (RTEL), 5p15.33 
(TERT), 9p21.3 (CDKN2BAS), 7p11.2 (EGFR) and so forth, these genes were 
only weakly associated with glioma, possibly reflecting molecular subsets12,13. 
 
 As for influence of environmental risk factors, it is difficult to prove a 
direct causation effect at this stage. This is taking into consideration the lesser 
number of studies, variability of risk factors and overall low statistical power. 
Expectantly, many of these risk factors, although often common in other 
human cancers, are likely to be merely chance associations in the context of 
GBM14. Therefore, the effect of diet choices15-17, tobacco smoking18,19, 
frequent use of mobile phones20,21 remain preliminary in GBM tumours at this 
stage20.To add pessimism to the situation, preventative measures, such as 
lifestyle changes, are ineffective in averting gliomas. Also, early diagnosis and 
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treatment unfortunately do not improve outcomes, precluding the utility of 
screening for this disease8. 
 
 Currently, the only established risk factor for glioma development is 
previous exposure to ionizing radiation (IR)8. Historical data from atomic 
bomb survivors replicated glioma-specific risks paralleled with a linear dose-
response at moderate doses22. In addition, 2 studies of childhood cancer 
survivors who had received relatively high dose radiation treatments for a 
primary cancer demonstrated a correlative increased risk of gliomas23,24. 
However, there are a few caveats to note in this context: firstly, in these 
epidemiological studies, the odds of an acquired neoplasm is not restricted to 
gliomas alone. Previous exposure to IR has also been found to be associated 
with other types of brain tumours, including meningiomas and schwannonas25. 
Next, although the link between IR and gliomas seem to be persuasive, this 
association is still not readily accepted in radiation science. One of the reasons 
is the longstanding concept of the brain being a highly differentiated organ 
with low mitotic activity, hence rendering it radioresistant26. Overall, we still 
need the input of high-quality, multi-centre studies, in order for better 
understanding of patient-environment interactions in the development of 
GBM. 
 
II. Presenting symptoms and imaging modalities 
 A key point of clinical frustration is that GBM tumours are generally 
diagnosed at an advanced stage27. They can become very large before 
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producing symptoms of raised intracranial pressure via cerebral oedema and 
mass effect28. In the acute setting, corticosteroids may be able to reduce the 
oedema through rearrangement of the blood-brain-barrier, lowering mass 
effect and intracranial pressure28. However, such measures are only temporary 
for relief of symptoms—the tumour still needs to be addressed. When a brain 
tumour is suspected, magnetic resonance imaging (MRI) with and without 
gadonilium contrast is the diagnostic investigation of choice29. In the T1-
weighted sequence, malignant gliomas typically enhance with gadonilium, and 
may have central areas of necrosis. These space-occupying lesions in the brain 
parenchyma are characteristically surrounded by white matter oedema. 
Malignant gliomas tumours are often unifocal, but infrequently, can be 
multifocal8. 
FIGURE 1: Representative MRI brain axial sections of T1-weighted post-
gadonilium showing: A. unifocal GBM in the left temporal lobe, and B. 
scattered, multifocal GBM lesions in brain parenchyma (Red arrows 
point to the lesion(s) of interest) 
 





III. Current treatment options 
 Despite notable advances in understanding glioma biology over the last 
few decades, the overall prognosis of GBM patients remains abysmal. At 
present, the ‘Stupp Protocol’ is the accepted standard of care for the 
management of GBM; it consists of maximally safe surgical resection, 
followed by concomitant radiation therapy and chemotherapy in the form of 
temozolomide (TMZ)30. However since its implementation in 200530, the 
median survival period for malignant gliomas remain between 12-18 months. 
After first-line treatment, virtually all GBM patients experience disease 
progression after a median Progression Free Survival (PFS) of 7-10 months31. 
Long-term survival is less than 30% at 1 year, 5% at 3 years and 3% at 5 years. 
This is largely due to high rates of local recurrence: tumours typically recur 
within 2 cm of the operative site, but occasionally in some cases recurring 
further away from the primary site32.  
 
Temozolomide (Temodal®) 
Given that complete surgical resection is not realistic in GBM, 
adjuvant therapies play an important role in the overall treatment. 
Temozolamide (TMZ), an alkylating agent, has proved to be an effective 
chemotherapy drug with relatively good side effect profile. It has 100% 
bioavailability as an oral agent33. Under physiological conditions, the blood-
brain-barrier (BBB) protects the CNS, preventing systematically administered 
chemotherapeutic strategies to enter the brain parenchyma34. Paradoxically, 
under such circumstances, the BBB becomes a key limiting factor for GBM to 
20 
 
be adequately treated. In patients with GBMs, there is increased capillary 
permeability from the breakdown of the BBB, causing a known clinical 
phenomenon called vasogenic oedema. This is a common event principally 
seen in brain tumours35. The concern in GBMs is the overall lack of 
penetration into the otherwise unaffected brain parenchyma where the BBB is 
intact. This implies that firstly, a higher dose of drugs is required to reach the 
tumour of interest, and next, the drugs may not be able to effectively reach 
microscopic tumour cells that have infiltrated the normal brain tissues. 
However, owing to its small size and lipophilic properties, TMZ is able to 
cross the BBB more effectively compared to other chemotherapy drugs. Its 
concentrations in the central nervous system (CNS) are about 30% of plasma 
concentration. Once it has entered the CNS, TMZ is converted to the active 
metabolite, methyltriazene-1-yl-imidazole-4-carboxamide (MTIC). These 
pharmacological properties make it an ideal agent for treating CNS 
malignancies.  
 
However, while concomitant adjuvant radiotherapy and TMZ offer a 
survival advantage over older chemotherapies, the improvement in median 
survival remains marginal, increasing only by 2 to 2.5 months30,36. 
Furthermore, despite survival benefit of TMZ, Stupp et al 2005’s landmark 
study did not stipulate the relative contribution of drug administration during 
radiotherapy from the contribution of adjuvant therapy. Instead, the authors 
hypothesized that concurrent administration of both play important roles in 
enhancing the overall outcome37. Presently, the exact mechanism of how both 
combined therapies work together as an entity is still uncertain. However, 
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owing to TMZ’s systemic tolerability, and lack of a better option for such a 
devastating disease, the use of the Stupp Protocol is current standard 
management for GBM today. 
 
Radiation therapy 
Despite IR exposure being identified as a significant risk factor (as 
previously mentioned), the paradoxical reality is that radiation therapy (RT) 
plays a central role in the treatment of brain tumours, and is considered the 
most efficient non-surgical intervention for malignant gliomas38,39. 
  
 In GBM, the clinical practice of involved field RT, which is delivery of 
RT only to affected regions of the brain, is the standard approach for adjuvant 
RT. This rationale for limiting the RT field is based upon the observation that, 
following whole brain RT, recurrent GBM typically develop within 2 cm of 
the original tumour site in 80 to 90% of the patients32,40,41. Earlier studies also 
[sl1]demonstrated that a higher RT dose delivered to a smaller volume resulted 
longer patient survival time42.In order to encompass infiltrating tumour cells, a 
total RT dose of 60 Gy is focused into the tumour cavity, plus a margin of 
radiographically normal tissue. Clinical data showed that RT doses beyond 60 
Gy caused substantial toxicity to the brain parenchyma, triggering necrosis 
and, or leukencephalopathy43. Hence, the choice of 60 Gy as a cumulative 
dose has been clinically correlated with safety and patient survival44,45. In 
present times, we have the advantage of much improved and safer RT 
technology due to rapid progress in informatics, imaging and the delivery of 
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high-precision beams46. These improved technologies of planning and delivery 
of RT have increased the target precision in the brain parenchyma while 
limiting either the dose given to the normal tissues in the brain or the volume 
of normal tissues exposed to the high doses47. 
 
IV. Tumour Recurrence 
 One of the historical figures of neurosurgery, Walter Dandy, was the 
first to report GBM recurrence in the contralateral hemisphere after 
prophylactic radical hemispherectomy48. In spite of advancements in 
understanding the disease, the inevitability of tumour recurrence is accepted as 
the most notorious feature of GBM behaviour. As previously mentioned, 
studies that had analysed GBM recurrence patterns conclude that the vast 
majority of neoplastic cells are likely found centrally within the original 
tumour bed and, or up to 2cm beyond its radiographically-enhancing 
borders49. However, migrating cells are centimetres away from the tumour and 
occasionally, even in the contralateral hemisphere, provide the basis for the 
universal recurrence of these tumours7. 
 
Typically, patients succumb to tumour recurrence within 12 to 18 
months. Several studies have demonstrated that the addition of TMZ to 
radiotherapy do not alter the fact that the most of the first relapses occur close 
to the original enhancing disease49-52. At the time of relapse, prognosis is 
particularly poor, with reports of near-100% mortality within 18 months. At 
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present, there is no standard treatment for patients with GBM recurrence after 
prior chemo-radiation therapy53.  
FIGURE 2: Time-sequential MRI brain axial sections of T1-weighted 
post-gadonilium showing tumour recurrence: A. Pre-operative scan with 
GBM in left fronto-temporal lobe, B. Immediate post-operative scan 
showing good tumour resection, and C. Scan image from MRI 6 months 
post-surgery, depicting tumour recurrence in surgical cavity (Red arrows 
point to tumour cavity) 
 
(Courtesy of Department of Neurosurgery, NNI) 
 
V. Salvage therapies currently in use 
Tumour debulking 
 
The goals of re-surgery after tumour recurrence are firstly, to relieve the raised 
intracranial pressure caused by the space-occupying lesion for life-saving 
purposes; and next, for cytoreduction to reduce tumour burden within each 
patient. Up to this day, the practice of tumour debulking with extent of 
resection (EOR) ≥98% is currently the only factor known to improve patient 
survival54.Nonetheless, in these cases, the effects of the re-operation are only 
temporary and impacts on the patient are at best, palliative. The following 2 
chemotherapeutics to be discussed have been used in for a select group in 
these patients. However, they are costly, have potentially life-threatening side 
effects and their benefits, if present, are unexceptional. 
 




Carmustine (BCNU (1,3-bis (2-chloroethyl)-1-nitrosourea)) has a long-
standing history in GBM. It was one of the first drugs to be approved by the 
U.S. Food and Drug Administration (FDA) to treat malignant gliomas. BCNU 
is an alkylation agent that interferes in tumour development by inhibiting 
DNA synthesis and repair55. However, BCNU proved to have pharmacokinetic 
drawbacks: it has a short half-life and low oral bioavailability56. To overcome 
these shortcomings, Gliadel® wafers were developed to deliver local 
chemotherapy through carmustine-impregnated wafers to concentrate 
chemotherapy in the pre-cancerous peritumoral surgical cavity57,58. These 
wafers consist of 200 mg biodegradable polymer discs (1 mm width and 1 cm 
in diameter) that contain 3.85% BCNU by weight59.  
 
Initially, BCNU wafers implanted intra-operatively were shown to be 
effective in improving outcome in some studies60. However, subsequent 
studies showed that the addition of Gliadel® did not appear to significantly 
improve clinical outcome and was associated with increased cytotoxicity61. 
Even after tumour removal and addition of these wafers into the tumour 
cavity, the overall survival benefit remains modest. At present, in our local 
institution, the use of Gliadel® wafers are mostly reserved for patients who 







Over the years, a number of angiogenic  agents have failed to 
demonstrate measurable efficacy in randomized trials53. However, 
bevacizumab, a monoclonal antibody to vascular endothelial growth factor 
(VEGF), managed to receive substantial attention in the past few years. 
However, there is recent consensus that despite the undeniable benefit, 
concerns regarding utility, indication, efficacy and side effects have been 
raised for its use in malignant gliomas62. We are now aware that not all GBMs 
are sensitive to anti-VEGF treatment63. In addition, some tumours that were 
initially sensitive to sensitive to the bevacizumb recurred with a more 
aggressive phenotype64. In fact, MRI scans done in this group of GBM 
patients treated with bevacizumab showed the development of multifocal 
recurrence that strongly indicated the presence of an infiltrative-invasive 
pattern65. Similar to BCNU, the use of bevacizumab is offered to patients who 
present with recurrent GBMs that are refractory to standard treatment protocol 
in our local institution. 
 
1.2. Therapeutic resistance in human glioblastoma: current concepts 
Since gliomas were first recognized in the mid-19th century, we have 
accrued a tremendous amount of data on this disease but have enjoyed little 
improvement in its survivability66.Like all cancers, a major obstacle in GBM 
treatment is its resistance to anticancer modalities67. As notably observed in 
modern brain imaging, true responses with partial or complete regression of 
tumour are rare in GBMs. This is an indication that current treatments, if 
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successful, arrest growth rather than actually kill68.  To add on to GBM’s grim 
profile, we are also aware that none of the available salvage treatments has 
shown real evidence of improved survival8. Therefore, delaying onset of 
recurrence or the extent of tumour dispersal will represent a significant 
advance in managing this disease27. 
 
There are several mechanisms and molecular abnormalities known to 
be involved in GBM therapeutic resistance, including genetic changes and 
variability, increased expression of target proteins, alteration of drug target, 
failure of the therapy to reach or enter target cell, increased DNA damage 
repair, reduced apoptosis and so forth. In addition, as previously mentioned, 
the presence of the BBB makes it challenging for therapies to penetrate the 
brain. All these cumulative factors add to this particular tumour being able to 
persistently evade both current and novel therapies. Although there are several 
factors involved in GBM therapeutic resistance, the following are commonly 
implicated: 
 
I. Tumour heterogeneity 
 GBM is characterized by a variety of genetic abnormalities. This 
phenomenon of inter- and intra-tumoral heterogeneity raises therapeutic 
challenges, because cells bearing different abnormalities may respond 
differently to therapy34. Studies have shown that there is a considerable 
evidence of heterogeneity within GBM tumours in a variety of biological, 
physiological and biochemical properties69,70 among subclones of the same 
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tumour in their response to adjuvant treatment71-73. Therefore, the unfortunate 
reality implies that attempts at treating subpopulations within a single lesion is 
likely futile in completely eliminating all tumour cells. 74,75. However, at this 
stage, the identification of surviving cells responsible for tumour recurrence 
has yet to be clinically confirmed. 
 
II. MGMT (O6-methylguanine DNA methyltransferase) 
 The enzyme O6-methylguanine-DNA transferase (MGMT) functions 
as a DNA damage repair entity. MGMT encodes a DNA repair protein that 
removes alkyl adducts at the O6 position of guanine, and less frequently, at the 
O4 position of thymine76. In normal cells, endogenous MGMT expression 
protects them from carcinogens; however, on the contrary, it can also protect 
cancer cells from chemotherapeutic alkylating agents, such as TMZ77,78. The 
flurry of interest in MGMT was a consequence of a publication following 
Stupp et al 2005’s landmark paper that resulted in the establishment of the 
now famous ‘Stupp Protocol’30 by Heigi et al79. This study attempted to 
identify patients who would benefit from the addition of TMZ to radiotherapy. 
Here, the authors found that methylation of MGMT promoter turned off its 
own gene transcription. This in turn, caused reduction in intracellular MGMT, 
and thereby inhibiting the DNA repair mechanism. According to their results, 
although the benefit was small, patients with a methylated promoter 
demonstrate a longer progression-free survival with chemotherapy plus 
radiotherapy37. The TCGA effort also found that in their cohort of GBM 
tumours, the MGMT promoter methylation status correlated with mismatch 
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repair deficiency and a hypermutator phenotype—all of which are known to 
be associated with resistance in GBMs80. 
 
However, owing to the immense complexity of GBMs, we 
acknowledge the contribution of this particular gene in therapeutic failure is 
not singular. Despite this, the methylation status of MGMT remains to be the 
most well-studied molecular feature in GBM at this point in time81, with both 
large-scale molecular80 and clinical79,82 data to substantiate its significance. It 
is hence imperative, that it maintains its bearing in GBM, until proven 
otherwise. 
 
III. Glioma stem cells 
The cancer stem cell model proposes that firstly, a tumour is organized 
according to the cell hierarchy of the organ in which it arises. Next, it is driven 
and maintained by a minority of transformed population of tissue-specific 
stem and, or progenitor cells83,84. At present, the debate regarding whether if it 
is the tumour stem cell, progenitor counterpart or both that is the actual 
contender for the disease remains unresolved39. Incidentally, this concept is 
not novel in GBMs. In 1926, the father of neurosurgery, Cushing, together 
with Bailey  had already proposed the idea of brain tumours arising from 
progenitor cells85. In addition, GBM is also one of those tumours in which 
cancer stem cells have been identified. These so-called ‘glioma stem cells’ 
(GSCs) are thought to be responsible for maintaining tumours post-therapy 
and re-populating them after gross total surgical resection. Moreover, it has 
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also been shown that the most aggressive and, or refractory cancers, usually 
contain the highest number of cancer stem cells86,87. The natural history of 
GBM is in concordance with this, thus reinstating the therapeutic importance 
of this particular cancer cell subpopulation. 
 
1.3. Molecular classification of glioblastoma 
Current WHO classification for gliomas 
At present, glioma patients are diagnosed according to 
histopathological findings. This relies on a morphology-based classification 
from the World Health Organization (WHO) criteria1. Essentially, the WHO 
system divides diffuse gliomas into tumour subsets: astrocytomas, 
oligodendrogliomas and oligoastrocytomas. These glial-based tumours are 
then graded into increasing histological degrees of malignancy (WHO I, II, III, 
IV). Malignancy features include the presence of nuclear atypia, mitotic 
activity, microvascular proliferation and necrosis. Based on the current WHO 
criteria1, malignant gliomas refer to those that fall under the WHO III and 
WHO IV tumours. As previously mentioned, the overall prognosis is 








TABLE 1: WHO Classification of glial tumours (Adapted from Louis et al 
(2007)1) 













Moderately increased cellularity 
Absent mitotic activity 





Distinct nuclei atypia 
Increased cellularity 
Marked mitotic activity 






Pleomorphic tumour cells 
Distinct nuclei atypia 
Increased cellularity 
Brisk mitotic activity 
Presence of microvascular 
proliferation and, or necrosis 
 
(Note: this table is not exhaustive. For the purposes of this project, the focus 













FIGURE 3: Microscopic haematoxylin-eosin slide pictures of a GBM 
tumour showing evidence of: A. Mitotic activity and, B. Microvascular 
proliferation. In general, both slides demonstrate areas of increased 
cellularity, nuclei atypia and tumour cell pleomorphism. (Note: the 
surgery of malignant gliomas uses a cytoreduction approach whereby the 
tumour is removed as much as possible with preservation of normal brain 
margins. Hence, normal brain tissue is not usually removed, especially in 



















(Pictures and analysis courtesy of Dr Tang YL, TTSH Pathology, and Dr B 
Yan, KKWCH Pathology) 
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Although the WHO classification for gliomas is still used as the 
standard method of the diagnosis in clinical practice, we are aware that as a 
visually-based criteria, it is likely to have certain limitations, such as 
subjectivity and the risk of inter-observer variations88,89. What has become 
clear in recent years is that cancer cells, although may have morphological 
similarities, are functionally heterogeneous90. Furthermore, observation from a 
clinical standpoint is the variable response of the patients with the same 
histological diagnosis towards standard treatment. ‘Glioblastoma multiforme’ 
as aptly termed by Harvey Cushing has been a challenging disease to 
understand owing to its notorious heterogeneity.  
 
Insights into glioblastoma subtyping 
At present, the traditional view of human cancers, including GBM, as a 
homogeneous population is considered obsolete90. With the advent of genome-
wide profiling studies, we are now aware of the existence of molecular 
subclasses within GBM80,91-94. This has been made possible with the 
development of various high-throughput genomic technologies to allow 
comprehensive surveys of human cancer genomes80.In 2006, the National 
Cancer Institute (NCI, USA) initiated an effort known as The Cancer Genome 
Atlas (TCGA) Research Network to generate a comprehensive catalogue of 
genomic abnormalities driving tumorigenesis in several cancers80, including 
GBM. The exercise was based on the observation that GBM, although 
histologically identical, will be heterogeneous at a molecular level. More 
importantly, the aim of deeper subtyping was to enable the use of identified 
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molecular traits in patient prognosis stratification, independent of currently 
used clinical indicators. In their landmark paper, TCGA provided a detailed 
view of the genomic changes in a GBM cohort containing 206 patient 
samples80. This initiative was followed by a series of studies that has since 
proven the existence of 4 molecular sub-groups (Proneural, Neural, Classical 
and Mesenchymal) based on gene expression, genetic aberrations and survival 
profiles. TCGA complied their findings with the input of gene expression, 
microarray-based comparative genomic hybridization (aCGH), methylation 
status and miRNA data. This cumulative data was subsequently correlated 
with patient demographics such as age, gender, diagnosis, treatment and 
survival patterns. 
 
FIGURE 4: Diagram showing GBM molecular subtyping findings by 






In essence, the introduction of gene expression profiling has provided 
researchers a useful method to classify tumours96-98. This is useful from a 
clinical perspective: a more insightful classification will be able to help the 
managing physician better delineate a general diagnosis. This is helpful in 
firstly, guiding clinical decision-making and next, in allowing effective 
disease prognostication. More importantly, molecular details in the 
classification can help us to identify areas of knowledge deficit for research. 
Examples of malignant primary brain tumours that have been exponentially 
better understood from molecular subtyping include medulloblastomas98 and 
ependymomas99. However, in the context of GBM, in the current TCGA 
subclasses ‘Proneural, Neural, Classical and Mesenchymal’, exact 
mechanisms underlying the relationships of some subtypes to neural 
differentiation and patient survival remain unknown at this stage93,95. 
Nonetheless, as a result of the TCGA initiative, other efforts were attempted to 
assess whether GBMs could be further subdivided into protein-based subtypes 
for better prognositication100,101. Despite their promising results, direct genetic 
links to protein subtyping remain incomplete at this stage. 
 
In addition to mRNA data, the TCGA database also included an 
extensive molecular network for GBM involving miRNAs102. Together with 
the recent insights of experimentally-validated miRNAs103and mRNA-miRNA 
networks102, miRNA-mediated mechanisms are now cited as key contributors 
to GBM’s notorious heterogeneity. A method attempting to elucidate these 
potential relationships was described by Kim et al 2011104. Here, the authors 
used a high-throughput microRNA approach for expression-based clustering 
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to identify clinically and genetically distinct glioblastomas subclasses. Their 
findings showed that in contrast to mRNA-based GBM subclasses, miRNA-
defined GBM subclasses demonstrated strong differences in genetic alterations, 
patient demographics, treatment response and patient survival104. 
 
FIGURE 5: Diagram showing the developmental taxonomy of 5 miRNA 







1.4. MicroRNAs in human glioblastoma 
Introduction: overview of miRNAs 
MicroRNAs (miRNAs) are a relatively novel class of small, non-
coding molecules typically 22 nucleotides in length105. They are highly 
conserved and account for approximately 1% of the human genome106. Of 
significance is that many miRNAs are tissue-specifically expressed107. Thus 
on this basis, it is expected that miRNA expression profiles will help to guide 
functional studies in various developmental pathways108. The exact number of 
miRNAs genes in the human genome is still unknown and previously 
estimated to be range from 500 to 1000108,109. However, the recent miRBase 
report showed the number of human mature miRNAs to exceed 2,500 (release 
21, June 2014). The established roles of miRNAs include the regulation of 
gene expression, organogenesis, and not surprisingly, tumorigenesis110-112.  
 
MicroRNA biogenesis is a multi-step process. (See Figure 6). They 
begin as long primary stem-loop transcripts (more than 1 kb) encoded by a 
cell’s own genome: these being termed as ‘pri-miRNA’. Pri-miRNAs are 
wrapped in hairpin-stem-loop secondary structures that undergo a 2-step 
maturation process, to eventually produce the functional miRNA.  Essentially, 
miRNAs are transcribed by RNA polymerase II (Pol II) into long primary 
miRNA transcripts that are cleaved in the nucleus by the RNase III (Drosha). 
The end-product is a hair-pin precursor called a pre-miRNA. Pre-miRNA is 
then exported from the nucleus to the cytoplasm by Exportin 5. Once in the 
cytoplasm, it is processed by the Dicer enzyme which produces a transient 
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miRNA duplex. Next, a single strand of the miRNA duplex is incorporated 
into a protein complex called the RNA-induced silencing complex (RISC)113. 
Once in this functional state, they are ready to regulate their target gene 
expression transcriptionally and post-transcriptionally via interaction with 
complementary mRNAs. In mammals, miRNAs are negative regulators of 
gene expression114; they can inhibit protein translation, leading to a subsequent 
downregulation of their target protein expression. Notably, a single miRNA 
can potentially regulate a wide range of target genes resulting in a global 
impact on gene expression115.This characteristic implies that by inhibiting one 
miRNA, we can potentially suppress multiple genes, subsequently silencing 
whole pathways116. 
 
FIGURE 6: Schematic diagram outlining miRNA biogenesis in a 





In the context of GBM, the targets and modulators of therapy have 
traditionally been DNA, mRNA and proteins. Therefore, mutations, copy 
number changes, and epigenetic variables at the DNA level and expression 
changes at the mRNA and protein levels have been previously studied to probe 
mechanisms that determine the pharmacologic response117-121. Work from 
different groups studying global miRNA expression profiles and in-depth 
individual miRNA function has established that miRNAs have important roles 
in different aspects of gliomagenesis, including chemo- and radiation 
resistance114. Some miRNAs have more implications in GBM pathogenesis 
due to their wider targets, more robust miRNA binding sites, broader 
functional coverage and their multiple roles in comparison to other 
miRNAs114.Thus, miRNA-mediated mechanisms by connecting and 
establishing cross-talk between wide arrays of aberrant pathways and cellular 
functions may provide a global perspective to confront heterogeneous and 
challenging tumours like GBM114. 
 
Approximating miRNA function through mRNA target prediction 
In recent years, the development of miRNA high-throughput platforms 
such as hybridization-based microarrays, next-generation sequencing (NGS)122 
and amplification assays (RT-qPCR)123 has been effectively utilized for 
miRNA expression profiling124,125.  Building on this and with the valuable 
input of bioinformatics, the application of miRNA target prediction offers an 
optimistic route to the discovery of associated mRNA function, and vice 
versa103,126-129. Depending on the prediction database of choice, each will use 
39 
 
its own algorithm to predict miRNA targets from mammalian genomes via 
conserved sites in the 3’-UTRs of the complementary genes130. However, 
despite the attractive convenience of such programmes, a note of caution: it 
remains an open question as to how many verified miRNA targets in these 
heterologous systems are actually important targets in vivo108. Thus, a 
conscientious effort is still required to experimentally validate the predicted 
targets from such mapping programmes for biological certainty. 
 
1.5. Gaps in disease knowledge 
At present, it is difficult to discuss personalized medicine for GBM 
patients given the paucity of effective treatment options64. Up to date, the most 
conclusive prognostic factors for GBM are extent of tumour resection, age at 
diagnosis, and Karnofsky performance status131,132. Embarrassingly, these 
factors for GBM are considerably benighted, especially in present time, where 
other cancers can be prognosticated by molecular markers. Furthermore, 
targeted therapies aimed at survival pathways have achieved success in other 
cancers, whilst their efficacies remain stalemate in GBM6.  
 
At this point in time, the only predictors of patient outcome are age, 
WHO tumour grading based on histopathological subtype, and Karnofsky 
Performance Scale (KPS)54. The KPS index classifies patients according to 
their functional impairment. The scale compares effectiveness of different 
therapies and assesses prognosis in individual patients. Essentially, the lower 
the Karnofsky score, the poorer the survival for the illness133,134. Despite 
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research efforts in GBM, there is not yet a single or cluster of robust molecular 
markers that has been standardized for translational use in medical practice. 
Also, in the context of therapeutics, we have not significantly progressed 
beyond the Stupp Protocol initiated in 200530. The obvious step forward is to 
achieve better understanding of the complex molecular and cellular 
mechanisms leading to GBM resistance—an important pre-requisite to the 
identification of more effective strategies135.  
 
TABLE 2: Karnofsky Performance Scale (KPS) (Adapted from Karnosky 
and Burchenal, 1949134) 
KARNOFSKY STATUS KARNOFSKY GRADE 
Normal, no complaints. 100 
Able to carry on normal 
activities. Minor signs or 
symptoms of disease. 
90 
Normal activity with effort. 80 
Care for self.  
Unable to carry on normal 
activity or to do active work. 
70 
Requires occasional assistance, 
but able to care for most of his 
needs. 
60 
Requires considerable assistance 
and frequent medical care. 
50 




Hospitalisation indicated though 
death non-imminent. 
30 
Very sick. Hospitalisation 








1.6. Project outline 
Owing to the elusive nature of the disease, it is impossible to study 
every possible bio-target. Incongruously, it is also unrealistic to concentrate on 
only one of its facets. In essence, this project aims to elucidate the issues 
underlying therapeutic resistance in GBM. Based on previous discussions, we 
will draw on current disease understanding, with the implementation of new 
biological knowledge in the field and up-to-date techniques as a whole, to 
approach our aims. 
 
1.6.1. Hypotheses and objectives 
The following summarises the hypotheses and objectives of the project: 
Hypotheses 
Primary Hypothesis: 
There is a subpopulation of GBM cells that is resistant to standard chemo-
radiation therapy. 
Secondary Hypothesis: 
Therapeutically-resistant GBM cells are a molecularly distinct subpopulation 
whose properties are regulated by miRNAs. 
 The primary hypothesis is founded on the fact that GBM as a 
heterogeneous entity, consists of subpopulations with different genotypes and 
phenotypes that have divergent behaviours136. As a result, within the tumour 
itself, we postulate there is a subpopulation that is resilient to the effects of 
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standard therapeutics in use today. Based on the existence of such a 
subpopulation, our secondary hypothesis is that they are a unique subgroup of 
tumour cells whose resistance properties are influenced by miRNAs. 
 
Objectives 
1. To demonstrate a subpopulation of GBM cells is resistant to chemo-
radiation therapy. 
2. To examine whether different miRNA expression underlying GBM 
heterogeneity contributes towards resistance in chemo-radiation therapy. 
 
Building upon our hypotheses, we state the key objectives for the project. 
Firstly, if such a therapeutically resistant subpopulation exists, it is imperative 
that the experimental models in our setup has to reflect what is observed in 
vivo as much as possible. Hence, they have to remain viable in the presence of 
clinically relevant treatment. Next, based on the assumption that this 
subpopulation will have its own genomic signature, we intend to use miRNA 






































MATERIALS AND METHODS 
2.1 Cell culture 
Immortalized human glioblastoma cell line LN229 from American Type Cell 
Collection (ATCC) was a kind gift from from A/Prof Too HP’s laboratory 
(Department of Biochemistry, National University Singapore). The cell line 
was commercially authenticated using Short Tandem Repeat (STR) profiling. 
(See Supplementary Data). These cells were grown in DMEM (Sigma, USA), 
supplemented with 10% FBS (Hyclone, USA), 100 U/mL penicillin and 100 
U/mL streptomycin (Life Technologies, USA).  Subsequently, cells were 
maintained in a 37°C in a humidified incubator containing 5% CO2 and 95% 
air. 
 
2.1.1 Development of temozomolomide-resistant glioblastoma cells 
The TMZ-resistant (TMZ-R) cell lines used in this study are a kind gift 
from Dr Ho YK and A/Prof Too HP (Department of Biochemistry, National 
University Singapore). Here, they adapted a method described by Le Calve et 
al 2010137 to generate TMZ-resistant cells of various drug resistance doses 
from GBM cell line LN229. Initiating treatment at 2.5 M, cells were cultured 
in complete medium in the presence of incremental TMZ concentrations: 2.5, 
5, 10, 20, 40, 80, 160 and finally 320 M. During the selection of resistant 
clones, the cells adapted to TMZ for approximately 30 days before exposure to 
the next dose. Subsequently, the cell panel was cultured in complete media 
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containing respective doses of TMZ to maintain their acquired 
chemoresistance138.  
 
FIGURE 7: Schematic diagram showing method of generating TMZ-




2.1.2. Selection of clinically relevant temozolomide-resistant glioblastoma 
cells for experiments  
The selection of appropriate in vitro models from the LN229 TMZ-R 
panel was corroborated with relevant literature. From patient studies, the 
predicted peak concentrations of TMZ were found to be in the range of 2.9 to 
6.7 mg/ mL in human glioma tumours, and 1.8 to 3.7mg/mL in normal brain. 
This was calculated with the total drug exposure, as indicated by the tissue: 
plasma area under the curve (AUC) ratio, which was about 1.3 in tumour 
compared with 0.9 in normal brain parenchyma139. Next, it is also known that 
TMZ has 100% oral bioavailability in patients140. Based on these data, we 
calculated an in vitro equivalent to a parallel concentration to what a GBM 
patient is likely to receive during actual treatment. Using the higher end dose 
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range of what a glioma tumour is likely to receive, that is, 6.7 mg/ mL, the in 
vitro concentration was calculated to be approximately 34 M. In order to 
simulate possible TMZ-resistance, the closest dosage and 2 more even more 
TMZ-resistant lines in the LN229 cell panel were selected—40 M, 80 M 
and 160 M. These TMZ-R cell lines are used in Chapter 3 experiments. The 
TMZ dose of 34 M was set as the ‘clinically relevant’ dose for in vitro 
treatment of cells, as reflected in Chapters 3 and 4. 
 
2.1.3. Isolation of glioma ‘stem cell-like’ population from glioblastoma 
cells 
The method used for the development of this subpopulation was 
adapted from the literature141,142. In essence, a chemically-defined media 
composed of 3:1 mix of DMEM (Sigma, USA) and Ham’s F-12 Nutrient 
Mixture (Life technologies, USA), the following were added: 1x B27 serum-
free supplement (Life Technologies, USA), 20 ng/mL EGF (Sigma, USA) and 
20 ng/mL bFGF (Sigma, USA). Sub-selected cells were then split into 3 
separate clonal populations, labelled 1 to 3 respectively. These 3 clones were 
used as biological replicates for subsequent experiments. These LN229 ‘GSC-







2.2 Proliferation assay 
The proliferation properties of LN229 parent and TMZ-R variant cells 
were compared using 2 different methods: cell counting to calculate their 
doubling times, and 5’bromo-2’deoxyuridine (BrdU)-incorporation into 
cellular DNA using a BrdU ELISA colorimeteric assay.  
 
2.2.1. Cell counting 
The cells are plated a 0.5 x 104 cells per well in 12-well plates. One 
plate is used for each time point. All cells are starved overnight and given 
serum media the following day. At the required time point, the cells are 
washed, trypsinzied and counted with a haemocytometer. Tryphan blue 
exclusion technique was used to ensure only the viable cells were included. 
This technique was applied throughout Chapters 3, 4, 5 and 6. 
 
2.2.2. BrdU (5-bromo-2’-deoxyuridine) ELISA assay 
The experiment was performed according to the manufacturer’s 
instructions in Cell Proliferation ELISA, BrdU Colorimeteric kit (Roche, 
USA). BrdU is an analogue of thymidine that gets incorporated into the DNA 
of proliferating cells in place of thymidine. This assay is hence, based on the 
detection of BrdU incorporation into the newly-synthesized DNA during cell 
proliferation. Briefly, cells were plated at 0.2 x 104 cells per well in 96-well 
plates. Each cell type was plated in quadruplicates and one plate was used for 
each time point. To ensure cell number efficiency for each assay, the control 
cell line was additionally plated in incremental numbers (500 to 1.6 x 104 cells 
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per well) on the same plate for a standard curve. All cells were serum-starved 
overnight and given BrdU (10nM) in serum culture media the following day. 
At each required time-point, absorbance values were measured using ASYS 
UVM340 microplate reader at 450 nm wavelength (reference wavelength: 
690nm).  Next, the raw values were quantified and normalized to the control 


















2.3. Migration assays 
2.3.1. Wound healing assay 
Silicon inserts (ibidi®, Denmark) were used according to the 
manufacturer’s instructions. The use of these inserts and subsequent data 
analysis for in vitro migration experiments has been previously described143-145. 
Essentially, 1 x 105 cells in 90 L culture media were plated in each side of 
the silicon chamber. The cells were allowed to adhere overnight within each 
chamber insert. After 24 hours, the silicon inserts were removed. 2 mL of 
regular culture media is then allowed to fill each well. At the required time 
point, photographs of the wound healing assay in per sample were taken in 
triplicates at 20x magnification. The pictures were subjected to WimScratch™ 
software analysis (ibidi®, Denmark) where the results expressed as a ratio 
of %scratch area : %cell-covered area per sample. The cell line, MDA-MB-
231 was used as a positive control for this assay. This assay was used in 
Chapter 3, Section 3.2.3. 
 




2.3.2. Transwell migration assay 
The cells used for the experiment were serum-starved overnight in 1%  
FBS cell culture media. The following day, 5 x 104 cells in 1% FBS culture 
media were seeded on the surface 8 μm pore-size filters per transwell 
(Corning® Costar®, USA). Cell culture media with 20% FBS was used as a 
chemoattractant in the lower chamber.  At 24 hours post-incubation, cells on 
the upper  chamber  were  gently removed  while  cells  which  had  migrated  
through  the  transwell filters  were fixed with 75% analytical ethanol. Next, 
they were stained with 0.5g/mL Hoescht 33342 (Life Technologies, USA) 
and washed with 1x PBS to remove any unbound fluorescent conjugates. 
Photographs of the stained cells are taken with an inverted microscope and 
analysed with ImageJ ver1.48s software. The cell line, MDA-MB-231 was 
used as a positive control for this assay. This assay was used in Chapter 3, 
Section 3.2.3. 
 
FIGURE 9: Schematic diagram depicting cross-sectional view of a 








2.4. Transwell invasion assay 
Two different types of matrices were used independently in this 
experiment: BD Matrigel (BD Biosciences, USA) and Collagen I (BD 
Biosciences, USA). Each ECM-simulation matrix was diluted in cell culture 
media containing 1% FBS and coated on 8 μm pore-size transwell filters 
(Corning® Costar®, USA). The transwells with the ECM-simulation coating 
were left to polymerize overnight in a 37°C in a humidified incubator 
containing 5% CO2 and 95% air. Prior to plating, the cells planned for the 
experiment were serum-starved overnight in  1%  FBS cell culture media. The 
following day, 5 x 104 cells in 1% FBS culture media were seeded on the now-
polymerized matrix in each transwell. Cell culture media containing 20% FBS 
was used as a chemoattractant in the lower chamber.  At 24 hours post- 
incubation, cells on the upper  chamber  were  carefully removed  while  cells  
which  had  invaded  through  the  matrix-coated membranes were fixed with 
75% analytical ethanol. Next, the cells were stained with 0.5g/mL Hoescht 
33342 (Life Technologies, USA) and washed with 1x PBS to remove any 
unbound fluorescent conjugates. Photographs of the stained cells are taken 
with an inverted microscope and analysed with ImageJ ver1.48s software. The 
cell line, MDA-MB-231 was used as a positive control for this assay. 
 
FIGURE 10: Schematic diagram depicting cross-sectional view of a 





2.5. Cell viability assay 
2.5.1. Cell viability to determine temozolomide dose-response 
Cells were plated at 0.5 x 104 cells per well in a 96-well plate. The 
cells were allowed to attach overnight before drug treatment the following day. 
Incremental doses of TMZ (up to 800 M) in cell culture media are 
administered to the cells for 72 hours. DMSO was used as the vehicle control 
for the experiment. CellTiter 96®AQueousOne Solution MTS Assay (Promega, 
USA) was added to the cells and incubated at 37°C for an hour, according to 
the manufacturer’s instructions. Following this, the absorbance of the cells 
was read at 490 nm using a ASYS UVM340 microplate reader. All cell 
samples were plated and treated in triplicates. The cell viability absorbance 
results were analysed with GraphPad Prism ver6. This assay was used in 
Chapter 3, Section 3.2.4. 
 
2.5.2. Cell viability assay post-clinically relevant treatment 
Cells were seeded at 1 x 105 cells per well in 6-well plates. At 24 hours 
post-plating, they were subjected to one of the following regimens: DMSO 
control, TMZ only, RT only and combinatorial TMZ and RT. At the required 
time-point, the cells are washed, trypsinized and quantified using a 
haemocytometer. Cell viability was assessed using tryphan blue exclusion. 





2.6. Ionizing radiation assay 
(This experiment was carried out with the kind assistance of Dr Keith Lim and 
Miss Tan Poh Wee, Department of Radiation Oncology, NUHS) 
The protocol for this assay was adapted according to the literature146,147. 
Cells were seeded into either 12-well or 6-well plates (depending on the 
experiment), and subsequently placed in a water phantom to ensure dose 
homogeneity. This is a plastic water phantom with a density of 1.03 g/cm3, 
which is almost water equivalent. The phantom mimics the human body as it 
would interact with radiation (CIRS Inc., USA). Essentially, it is a material 
with a quantified mass similar to human tissue that is used to investigate 
radiation beam effects of on humans. Next, the plated cells were irradiated 
with a 6-MV photon generated by the linear accelerator (Elekta Synergy) at a 
dose-rate of 8.7 Gy/ min, with different doses (2, 4, 6, 8 and 10 Gy). In order 
to achieve a final dose of 60 Gy to be delivered in vitro, we applied the 
Biological Effective Dose (BED) formula148,149. From the BED, the required 
IR dose for the experiment was calculated to be 30 Gy, to be given over 3 
fractions at 10Gy per day. This gave us the biological effective dose (BED) of 
having given 60Gy to the cells or an Equivalent Dose in 2 Gy per day (EQD2) 
of 50Gy, more than sufficient radiation to deliver effective cell kill. This assay 







2.7. Quantitative RT-PCR 
Total RNA from the harvested cells of interest was isolated with 
TRIzol reagent (Life Technologies, USA) according to manufacturer’s 
instructions. The integrity of isolated total RNA was validated by denaturing 
agarose gel electrophoresis. One microgram of total RNA was reverse-
transcribed using 400U of ImPromII reverse transcriptase (Promega, USA) 
and 0.5g random hexamer (AIT Biotech, Singapore) for 60 minutes at 42°C. 
The reaction was terminated by heating at 70°C for 5 minutes. Next, gene 
expression levels were quantified by real-time PCR using gene-specific 
primers. Primers for the required genes of interest were listed as target cDNA. 
Real-time PCR (RT-qPCR) was performed on CFX96 (Bio-Rad, USA) in a 
total volume of 25L in 1X Xtensa Mix (MIRXES, Singapore), containing 
1L of cDNA sample, 2.5mM MgCl2, 100 nM of each primer, and 1.25U 
KlearTaq DNA polymerase (KBiosciences, UK). RT-qPCR was carried out 
after an initial denaturation for 10 minutes at 95°C, followed by 40 cycles of 
30 seconds denaturation at 95°C, 30 seconds annealing at 60°C and 30 
seconds extension at 72°C. Fluorescent detection was carried out during the 
annealing phase. Threshold cycles (Ct) were calculated automatically using 
the CFX Manager ver1.6 software (Bio-Rad, USA). The expression levels of 
the target genes were normalized to housekeeping genes in the same samples. 
This assay was applied in Chapters 3 (Section 3.2.2), 4 (Section 4.2.1), 



















FORWARD SEQUENCE (5’-3’) 
 
REVERSE SEQUENCE (5’-3’) 
GAPDH ATGGGGAAGGTGAAGGTCGG GACGGTGCCATGGAATTTGC 
β-actin AAGATCAAGATCATTGCTCCTC AACTAAGTCATAGTCCGCCT 
RPL19 TCAGGCTTCAGAAGAGGCT GGAGTTGGCATTGGCGATT 
BMI-1 TTCATTGATGCCACAACCAT CAGCATCAGCAG AAGGATGA 
CD133 AGAGCTTGCACCAACAAAGTACAC ACCAAGCACAGAGGGTCATTG 
FABP7 TGACCAACAGTCAGAACTTT GGAGGAGAGCAGAGAAGAGA 
Nestin GGAGGAGAGCAGAGAAGAGA AAGCCAGGACAGCAGGAT 
SOX2 TACAGCATGTCCTACTCGCAG GAGGAAGAGGTAACCACAGGG 
SOX9 CCCCAACAGATCGCCTACAG TCTGGTGGTCGGTGTAGTCGTA 
Vimentin TGCAGGAGGCAGAAGAATGG ATTTCACGCATCTGGCGTTC 
MGMT GTCGTTCACCAGACAGGTGTTA ACAGGATTGCCTCTCATTGCTC 
MLH1 TTCGTGGCAGGGTTTTG GCCTCCCTCTTTAACAATCACTT 
MSH2 GCTGGAAATAAGGCATCCAAGG CACCAATGGAAGCTGACATATCA 
MSH3 TGGAAAATGATGGGCCTGTTAAA AGACATTCCCAGATCACTTCCT 
MSH6 AGCTTAAAGGATCACGCCATC AAGCACACAATAGGCTTTGCC 
PMS1 GTTCTGGGGACTGCTGTTATG GGTCTGCATCACACTTTGGAA 
PMS2 GAAGGTTGGAACTCGACTGATG CGCACAGGTAGTGTGGAAAA 
ABCA3 GGAGAACTTCTATGCCTGGAG GGTGTATAATTCTGTCAGTGTCC 
ABCB1 TTCTACGGGAAATCATTGGT GGTGTCAAATTTATGAGGCAG 
ABCC3 GAATTCTGCAAGGGTTCTTGG GGTGTCAAAGAAGGACTGTG 
ABCG2 TCATGTTAGGATTGAAGCCA TTGTGAGATTGACCAACAGAC 
RFX1 GAAGCGACTGCCCAAAGC CACGTCGGGAATGAGGATTT 




The cells were washed with 1x PBS and subsequently lysed in 2% SDS 
lysis buffer as previously described by Wan et al143. Protein concentrations are 
quantified using the MicroBCA assay (Pierce, USA).  Each protein sample 
was then separated by 8% to 15% SDS-PAGE gel electrophoresis, transferred 
onto nitrocellulose membranes (Bio-Rad, USA) and blocked with 5% low-fat 
milk at room temperature. Next, the membrane was probed with primary 
antibodies to detect each protein of interest. Secondary antibodies appropriate 
for each primary antibody were probed for an estimated 60 minutes at room 
temperature. For both primary and secondary antibodies, the antibody dilution 
used followed as per the manufacturer’s recommendations, and adjusted 
accordingly if required. The protein bands were developed with Immobilon 
Western Chemiluminescent HRP Substrate (Millipore, USA) on a 
ChemiDocTM XRS+ system (Bio-Rad, USA). Subsequently, the band 
intensities were quantified using Image Lab v4.1 software (Bio-Rad, USA). 
This assay was used in Chapters 3 (Section 3.2.2) and 4 (Section 4.2.1). 
 






β-actin Sigma, USA (AC-15) mouse 
β-tubulin Santa Cruz Biotechnology, USA (H-235) rabbit 
MGMT Cell Signaling Technology, USA (#2739) rabbit 
FABP7 Cell Signaling Technologies, USA (#9597) rabbit 
MSI-1 Abcam, USA (ab97959) rabbit 





2.9. Soft agar colony forming assay 
Briefly, 1% gum agar (Sigma, USA) was melted in a microwave and 
cooled to 40°C in a water bath. Under sterile conditions, the melted agar was 
mixed with equal volumes of culture media to form the base mixture. This 
final mixture concentration consisted of: 0.7% agar + 3:1 (DMEM: F12) + 1x 
B27 + 20 ng/mL bFGF + 20ng/mL EGF. The base agar was allowed to 
solidify at room temperature for approximately 30 minutes. In meantime, the 
top agar layer was prepared using 1% melted agar mixed with equal volumes 
of culture media containing cells. The cells of interest were dissociated with 
Accutase® (Life Technologies, USA) to ensure single cell suspension and 
manually counted.  Each top layer consisted of 1 x 104 cells in a final mixture 
concentration of 0.35% agar + 3:1 (DMEM: F12) + 1x B27 + 20 ng/mL bFGF 
+ 20ng/mL EGF.  Next, the cells were incubated at 37°C in a water-saturated 
incubator containing 5% CO2 and 95% air for 14 days. The cells were fed 
with culture media every 48 hours. The experiments were done in 12-well 
plates, using biological triplicates, each biological line with technical 
triplicates. Each plate included 2 wells containing only base and top agar 
layers (i.e. without cells) to serve as a background control for cell 
quantification. At the required time-point, the number of colonies were 
manually quantified using ImageJ ver1.48s software. This assay was used in 
Chapter 4 (Section 4.2.2). 





2.10. MicroRNA-related experiments 
2.10.1. MicroRNA profiling 
(The workflow described below was developed by Dr Zhou Lihan and Dr Zou 
Ruiyang, MiRXES, Pte Ltd and was carried out by myself in RSIC, an 
A*STAR facility dedicated to miRNA profiling.) 
The following assay was utitlised in Chapter 5 (Section 5.2.1). 
MicroRNA profiles were determined using a facile high performance real-time 
RT-PCR assay (modified stem-loop mediated reverse transcription 
quantitative PCR; mSMRT-qPCR) that allowed specific and rapid detection of 
mature miRNAs using fast thermo-cycling profile (10 seconds per 
cycle).123These assays were developed using a proprietary in-house designed 
algorithm based on thermodynamics principles and parametrizations derived 
from data-driven computational modelling. A standard workflow protocol 
dictated the miRNA profiling process. Essentially, it consisted of 3 key 
components as per following: 
I. Pre-analytics. 
Total RNA from up to 200 µL of cells was isolated with the phenol-
chloroform RNA extraction method as previously described (2.7. 
Quantitative RT-PCR). To reduce RNA loss and monitor extraction 
efficiency, isolation enhancers and spike-in control RNAs (MiRXES) were 




The isolated total RNAs and 7 dilutions (108 to 10 copies) of synthetic 
template RNAs were converted to cDNA in multiplex (60-plex) reverse 
transcription reactions. Since the concentration of the total RNA could be 
reliably quantified, the RNA input to the RT reaction is normalized by volume 
instead of quantity. Typically, 5 to 10% (volume) of total isolated RNA was 
used for each multiplex reaction. To detect the presence of inhibitors and 
monitor the RT-qPCR efficiency, a second set of spike-in control RNAs was 
added to the total RNA prior to the RT step. These spike-in RNAs, together 
with the ones added during RNA extraction step, were reverse-transcribed and 
detected by specifically designed assays. In addition, the spike-in RNAs were 
added in different amounts to assess the efficiency of the whole workflow in 
detecting high, medium and low abundance target miRNAs. The synthesized 
cDNA was then subjected to a multiplex augmentation step that specifically 
augments the cDNA content by 1,000 to 10,000 fold, without changing the 
representation of the miRNA. Next, the augmented cDNA was diluted and 
quantified in SYBR Green based single-plex qPCR. The cDNA of the serial 
dilutions of synthetic templates are simultaneously quantified and used to 
construct a standard curve that allows absolute quantifications of target 
miRNAs.  
III. Data processing and analysis. 
Upon completion of profiling, the raw Threshold Cycles (CT) values 
were processed and the absolute copy numbers of the target miRNAs in each 
sample were determined through intra-polation of the standard curves. The 
copy numbers of the spike-in control RNAs were simultaneously quantified 
for each sample. The technical variations introduced during RNA isolation and 
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the process of RT-qPCR was then normalized by the geometric means of these 
spike-in control RNAs. With the normalized data, a set of endogenous 
reference miRNAs that were stably expressed across all samples could be 
identified using multiple validated mathematical models. A combination of 
several stably expressed endogenous reference miRNAs is then used to 
normalize the biological variations in the samples. The final miRNA 
expression levels after normalization of both technical and biological 
variations were analysed with multiple statistical methods to identify panels of 
miRNAs with the highest discriminatory power between control and treated 
cells. For the purpose of increasing the robustness as well as reducing the 
chance of over-fitting, the features (miRNAs) were filtered by 2 criteria to 
form the candidate feature pool for the miRNA panel selection. The features 
with individually low ROC values (<0.7) of the ROC and signal-to-noise ratio 












2.10.2. Overexpression of selected miRNAs 
As per manufacturer’s instructions, 5 nM of miRNA mimic (Qiagen, 
USA) was used to overexpress the individual expression of the miRNA of 
interest in cells.  Each miRNA was  mixed  with  Lipofectamine  RNAiMAX®  
transfection  reagent (Life Technologies, USA)  in Opti-MEM  reduced serum 
media  (Life Technologies, USA), and allowed to stand at room temperature 
for 15 minutes before transfection. Approximately, six hours post-transfection, 
the transfection media was replaced with regular cell culture media. Medium 
GC content negative control (Life Technologies, USA) was used as 
experimental control. This experiment was performed in Chapter 5 (Section 
5.2.3). 
 
TABLE 5: Oligoribonucleotide sequences of miRNA mimics used 
miRNA of interest miRNA mimic sequence 
hsa-miR-125a-3p 5' ACAGGUGAGGUUCUUGGGAGCC 
hsa-miR-629-5p 5' UGGGUUUACGUUGGGAGAACU 










2.11. Microarray data processing and analysis 
(The following was carried out with the kind assistance of Dr Vivien Koh, 
Biopolis Shared Facilities, A*STAR) 
Total RNA was isolated from cell types of interest and subjected to 
microarray gene expression analysis using Illumina HT-12 v4 Expression 
BeadChips (Illumina, USA). Three independent biological replicates were 
profiled for each cell type of interest. The RNA was first biotinylated and 
amplified using the Illumina® TotalPrep-96 RNA Amplification Kit according 
to the manufacturer’s instructions, followed by cDNA synthesis, cDNA 
purification, cRNA synthesis and cRNA purification. Next, the samples were 
hybridized onto the arrays for 16 hours at 56°C. Arrays were washed and 
scanned using the Illumina BeadArray Reader. Data was then exported and 
analyzed using GenomeStudio v2011.11 software (Illumina, USA). This assay 











2.12. Predictive database analysis of miRNA-mRNA mapping 
(This analysis was carried out with the kind assistance of Dr Zhou Lihan and 
Dr Zou Ruiyang, MiRXES, Pte Ltd) 
The following analysis was utilised in Chapter 5 (Section 5.2.2). The 
online interactive tool miRror 2.0, was used for analysing experimental results 
under the notion of coordination in miRNAs regulation127. For a set of 
miRNAs, miRror 2.0 outputs a ranked list of gene targets according to their 
likelihood to be targeted by the miRNA ensemble and vice versa for a set of 
regulated genes. The miRror 2.0 algorithm then designates statistical criteria 
that were uniformly applied to a dozen miRNA-target prediction databases. 
Users are able to select the preferred databases for predictions and numerous 
optional filters that restrict the search to predictor scores150. Next, miRror 2.0 
converts all predictor resources results into a unified platform by incorporating 
a statistical measure according to the hyper-geometrical distribution127. Here, 
we set the following parameters for our mRNA target prediction: 1) the 
mRNA targets must be common to all 3 selected miRNAs; 2) 2 mRNA 
targets have to be simultaneously found in 2 independent miRNA databases; 
3) the statistical value of each predicted mRNA target has to be <0.05 (p 
<0.05). The predicted list of mRNA targets was subsequently mapped against 
all upregulated genes in the mRNA microarray data. Each confirmed mRNA 
target was then individually validated using RT-qPCR to confirm its 





2.13. Bioinformatics analysis with human clinical databases 
(This analysis was kindly assisted by Edwin Sandanaraj, Senior Research 
Fellow in Bioinformatics, NNI) 
The mRNA expression of genomic markers was evaluated in two 
independent glioma databases including REMBRANDT and Gravendeel 94,151. 
The REMBRANDT (Respository of Molecular Brain Neoplasia Data) patient 
glioma database contains data generated through the Glioma Molecular 
Diagnostic Initiative from 874 specimens94. The Gravendeel patient glioma 
database has cummulative data from 276 specimens from the Erasmus 
University Medical Centre tumour archive151.The required raw data was 
extracted from REMBRANDT and GEO database archive (GSE16011). The 
cel files were processed in mas5 algorithm using ‘affy’ packages implemented 
in R bioconductor 152,153. Clinical information of patients was collected from 
respective publication for statistical analyses. Probeset annotation for genomic 
markers was queried in ensemble human database with biomaRt packages 154. 
A standard one-way ANOVA model was fitted to assess the variability in gene 
expression across histological subtypes of glioma patients and statistical 
significance was evaluated at the level of 5% (p<0.05). Survival association 
for gene expression was estimated using tercile-based stratification of patients. 
A terciles approach ranks patients based on mRNA expression of individual 
gene and stratifies the population into three groups as low-, intermediate- and 
high-expression patients. Kaplan-Meier survival curves were plotted for the 
patient groups (terciles) and the statistical significance was evaluated by log-
rank test. In addition, a multivariate Cox Proportional-Hazards model was 
regressed to assess the independent association of covariates investigated. A p-
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value of <0.05 was considered to be statistically significant. Graphical 
illustrations were generated using CRAN packages such as beeswarm, survival 
and graphics 155-157. The results of these analyses are reflected in Chapter 6 
(Section 6.2.2). 
 
2.14. siRNA knockdown of selected genes 
As recommended by the manufacturer, 20 nM of siGENOME 
SMARTpool siRNA duplex (Dharmacon, USA) was used to individually 
silence the expression of each gene of interest in the cells.  Each siRNA was  
mixed  with  Lipofectamine  RNAiMAX®  transfection  reagent (Life 
Technologies, USA)  in Opti-MEM  reduced serum media  (Life Technologies, 
USA), and allowed to stand at room temperature for 15 minutes before 
transfection. Approximately, 6 hours post-transfection, the transfection media 
was replaced with regular cell culture media. Medium GC content negative 
control (Life Technologies, USA) and void-siRNA treatment were used as 









TABLE 6: Oligoribonucleotide sequences (4 in 1) in each SMARTpool 
siRNA 
















2.15. Statistical analysis 
Statistical analyses were performed using 2-tailed Student’s t-test or Analysis 
of variance (ANOVA) test, depending on the experimental setup. Differences 
between sample means were considered statistically significant when p-






















A subpopulation of LN229 human glioblastoma 
cells survives long-term temozolomide treatment 
but is sensitive to high-dose radiation 
 
‘A theory has only the alternative of being right or wrong. A model has a third 
possibility: it may be right, but irrelevant’ 
M. Eigen (1927-present) 













A SUBPOPULATION OF LN229 HUMAN GLIOBLASTOMA CELLS 
SURVIVES LONG-TERM TEMOZOLOMIDE TREATMENT BUT IS 
SENSITIVE TO HIGH-DOSE RADIATION 
3.1. Introduction 
Since the emergence of reports showing a survival benefit with the 
addition of TMZ to RT as a first-line treatment , TMZ has been the most 
studied agent in recurrent GBM, either as monotherapy or as the mainstay of a 
combination regimen158. As a result, there is a surge in the exploration of 
mechanisms underlying acquired TMZ-related resistance in GBM159-164. As a 
result, a popular in vitro method described to do so is the utilization of TMZ-
resistant (TMZ-R) GBM cell lines. These techniques of developing TMZ-R 
GBM cell lines have been well-described in literature137,161,165,166. Although 
this approach may not completely reflect the situation in vivo, it allows 
assessment of possible mechanisms triggered by repeated pulse exposure to 
TMZ167. In this chapter, the approach describes the assessment of LN229 
parent cell versus LN229 TMZ-R cell lines in the context of common cancer 









3.2.1. A subpopulation of LN229 cells demonstrates resistance towards 
commonly used GBM chemotherapeutics 
During a screen of a panel of human glioblastoma cell lines, LN229 
was noted to survive long-term incremental doses of TMZ treatment. To 
assess their resistance potential, LN229 TMZ-R variants were subjected to a 
TMZ treatment cell viability assay. In order to account for reproducibility, the 
results were counter-checked for cell viability doses at 50% in TMZ and 
BCNU against what is reported in the literature for TMZ-sensitive LN229 
cells. We found that our findings concurred to a similar range for both drugs in 
the literature168,169. For the LN229 TMZ-R variants, the panel displayed higher 
cell viability in comparison to the LN229 parent cells, in the presence of 
incremental doses of TMZ. (See Figure 12A). Under the same circumstances, 
it was also noted that LN229 TMZ-R cells cultured in higher doses of TMZ 
(hence, presumably more chemo-resistant) maintained better cell viability at 
higher doses of TMZ, in comparison to LN229 parent cells. In addition, a 
similar trend was observed when the same LN229 cell panel was treated with 
BCNU, another DNA-methylation agent. (See Figure 12B). The cross-
resistance across 2 commonly cited GBM chemotherapeutics suggests that in 
the presence of TMZ-resistance, the use of another agent may likely be futile 






FIGURE 12: A. LN229 TMZ-resistant variants demonstrate higher cell 
viability when treated with TMZ, as compared to the LN229 TMZ-
sensitive parent cells. B. In a similar trend, LN229 TMZ-resistant 
variants demonstrate higher cell viability when treated with BCNU, as 
compared to the LN229 TMZ-sensitive parent cells. 
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3.2.2. Acquired temozolomide resistance in LN229 human glioblastoma 
cells correlates with MGMT expression 
From the previous results (See Section 3.2.1), the cross-resistance of 
LN229 TMZ-R variants to both TMZ and BCNU was observed. As both 
chemotherapy agents are DNA methylation agents, such a phenomenon is not 
entirely surprising. The expression of MGMT, a gene well-studied in TMZ 
resistance for GBM patients was examined in the LN229 cell panel. (See 
Figure 13). MGMT is consumed when counteracting TMZ-induced damage, 
thus, intracellular levels of MGMT are expected to correlate with 
chemoresistance167. Our results identified 2 key findings: firstly, we were 
unable to detect MGMT at 35-40 cycles using RT-qPCR in TMZ-sensitive 
LN229 parent cells, concurring with our immunoblotting findings. The 
equation 2^-CT was used to quantify the PCR findings, thus assigning a 
relative value of 1 to LN229 parent cells. Next, there was an incremental 
expression of MGMT at both transcriptional and protein levels as LN229 
TMZ-R cells become more TMZ-resistant. In affected patients, there is 
already awareness that GBM tumours that actively express MGMT are more 
resistant to TMZ than tumours where the MGMT gene is absent170. 
Furthermore, there is some persuasive data supporting that a patient’s MGMT 
status influences GBM recurrence, to the point of prompting clinical studies to 
use a ‘re-challenge TMZ’ metronomic approach in these patients171-173. This 
practice is currently used for a select group of GBM patients with recurring 
tumours today in our local institution. Putting it all together, the preliminary 




FIGURE 13: A. mRNA expression of MGMT from RT-qPCR. B. Western 
blot showing protein expression of MGMT in LN229 parent and TMZ-R 
variant cells. (Jurkat cell line was used as a positive control for the 
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* p -v a lu e  < 0 .0 5
** p -v a lu e  < 0 .0 1
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Following the course of the previous findings, the mRNA expression 
levels of other transcription factors commonly related to therapeutic resistance 
in GBMs, such as the mismatch repair (MMR) and ATP-binding cassette 
transporters (ABC transporter family) genes was investigated. (See Table 7). 
 
TABLE 7: List of other genes investigated in the LN229 cell panel 








In this experiment, some of these genes showed changes at mRNA 
level. (See Figure 14). The decreased levels of MMR proteins has been 
reported to be involved in resistance to alkylating agents, including gliomas167. 
For example, MLH1 and MSH2 have been previously demonstrated to be the 
commonly mutated in human malignancies175.The absence of MLH1 was 
often associated with a high degree of TMZ resistance, and its resistance-
related mechanisms was also known to be independent of O6-alkylguanine 
DNA alkyltransferase levels175. These findings were also similar for MSH2, 
however, MLH1 deficiency was more common than MSH2 deficiency in the 
context of TMZ resistance175. 
 
In the LN229 cell panel, MLH1 and MSH2 were not detectable at 40 
cycles in RT-qPCR in all lines, including the LN229 parent cells. Since the 
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LN229 parent cells were able to survive incremental TMZ concentration to 
generate their resistant counterparts while other cell lines succumbed, it is 
hence not unexpected that the LN229 TMZ-R variant cells maintained this 
feature in their phenotype. In contrast, the mRNA expression of MSH3 and 
PMS1 was found to be significantly downregulated in both LN229 TMZ-R 80 
M and 160 M cells, in comparison to the LN229 parent cells. However, for 
the LN229 TMZ-R 40 M line, the reduction in expression was not 
statistically significant. The reduction in MSH3 and PMS1 for the LN229 
TMZ-R 80 M and 160 M cells concur with what has been previously 
reported in the literature167. In addition, although the inactivation of MSH6 
had been previously shown to mediate chemoresistance in glioblastoma 
cells176, a statistically significant reduction in its expression for all the LN229 
TMZ-R variant cells, in comparison to LN229 parent cells was not observed.  
 
High expression of drug efflux pumps, including the ABC transporter 
family of genes, has been previously shown to have the capacity to expel 
cytotoxic drugs, resulting in better cancer cell survival and thus promoting 
chemoresistance177,178. In this experiment, the majority of the ABC transporter 
family genes were either not detectable at 40 cycles in RT-qPCR (ABCA3 and 
ABCG2), or had reduced expressions (ABCB1 and ABCC3) in the LN229 cell 
panel, with the sole exception of ABCC3 in LN229 TMZ-R 40 M cells.  
 
Putting it all together, the results demonstrated that as LN229 cells 
become progressively more chemoresistant, MGMT expression was noted to 
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be incremental. However, the other chemoresistant genes did not show a 
similar trend to MGMT. In particular, LN229 TMZ-R 40 M was noted to be 
different its expression of MSH3, PMS1 and ABCC3 in comparison to its 
LN229 TMZ-R 80 M and 160 M counterparts. Nonetheless, the aim of the 
mRNA screening of these transcriptional factors was to seek a dose-dependent 
consensus in the expression of the TMZ-resistant LN229 cell lines, as 
previously demonstrated by MGMT expression at both mRNA and protein 
level. In this context, the RT-qPCR experiments for the undetectable genes 
can be repeated using the following cells lines U251MG for MLH1 and MSH2, 
and U87MG for ABCA3 and ABCG2, as positive controls, as verified from 
the literature. Overall, these findings suggest that the possible interplay and or, 
contributions by other genes, whether if they are independent of MGMT-
related mechanisms, in LN229 TMZ-R cells in the context of chemoresistance, 
















FIGURE 14: RT-qPCR showing mRNA expression of common genes 
cited in GBM chemoresistance. MLH1, MSH2, ABCA3 and ABCG2 were 
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3.2.3. Temozolomide-resistant LN229 human glioblastoma cells show 
similar tumorigenic hallmarks to temozolomide-sensitive LN229 cells 
 
A main feature of malignant tumours involve their ability to sustain 
chronic proliferation. In the case of normal tissues, homeostasis is maintained 
via the control of signals that initiate entry into and progression through the 
cell cycle. However, GBM cells have been known to dysregulate such signals, 
in order to continue cancer cell growth179. This experimental setup 
demonstrated the ability of LN229 TMZ-R variants to maintain similar 
proliferative rates as LN229 parent cells.  (See Figures 15A and 15B). In 
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addition, migrating GBM cells are known to be able to generate forces and 
subsequently distort into shapes, hence allowing them to move through brain 
structures27. It was that noted the LN229 cell panel showed similar migratory 
properties between parent and TMZ-R variant cells, another indication of their 
ability to conserve this aspect of neoplastic behaviour during acquisition of 
TMZ resistance (see Figures 16A and 16B). Another crucial feature of GBMs 
is their diffusely infiltrative nature. In clinical practice, we often encounter 
GBM tumours invading functional brain areas that make difficult for 
pathological tissues to be fully resected, inevitably affecting the patient’s 
outcome180. Owing to this malignant cell invasion, many treatments for GBM 
remain elusive181. These results demonstrate that LN229 TMZ-R variants 
retain the invasive properties as LN229 parent cells, in both types of simulated 
ECM matrices. (See Figures 17A and 17B). To conclude the findings in this 
section, it was observed that the in vitro ability of LN229 TMZ-R cells 
preserved their innate properties of 3 known cancer hallmarks, in comparison 
to LN229 parent cells: proliferation, migration and invasion, in the face of 












FIGURE 15: A. BrdU ELISA cell proliferation assay of LN229 parent 
versus LN229 TMZ-R variant cells. B. Cell counting experiment 
comparing LN229 parent versus LN229 TMZ-R variant cells. C. Cell 
cycle profile of LN229 parent versus LN229 TMZ-R variant cells. 
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FIGURE 16: A. Wound healing assay comparing LN229 parent versus 
TMZ-R variants. B. Transwell migration assay comparing LN229 parent 
versus TMZ-R variants. 
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FIGURE 17: A. Transwell invastion assay results of LN229 parent versus 
TMZ-R variants (Matrigel matrix). B. Transwell invastion assay results 
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3.2.4. Acquired temozolomide resistance in LN229 human glioblastoma 
cells demonstrates higher resistance to ionizing radiation compared to 
temozolomide-sensitive LN229 cells 
 
In this cell viability assay, the interest was to know if the panel of 
LN229 TMZ-R cells was able to withstand the effects of IR. The results 
demonstrated that the TMZ-resistant LN229 cells were generally more 
resilient to IR treatment in comparison to LN229 parent cells. Furthermore, 
within the LN229 TMZ-R variants, we noted that as the cells became 
increasingly TMZ-resistant, they were more viable in the presence of single-
dose IR treatment (2, 4, 6, 8 and 10 Gy). (See Figure 18). As IR causes cell 
damage by DNA strand breaks, and that MGMT functions as a DNA damage 
repair entity76, such findings were not unexpected. Putting these experimental 
outcomes together, an IR treatment dose-dependent relationship between 
LN229 TMZ-R cells that seemed to correspond to their respective MGMT 
expressions was observed. Here, as the MGMT expression increased in the 
cells from 40 M to 80M and finally, 160 M, there was likewise, a parallel 











FIGURE 18: Cell viability assay demonstrating the effects of incremental 
IR doses on LN229 parent versus LN229 TMZ-R variants. A single dose 
of IR (2, 4, 6, 8 and 10 Gy) was delivered to the cells at a dose-rate of 8.7 
Gy/min using irradiation with a 6-MV photon generated by the linear 
accelerator (Elekta Synergy). The cells were harvested and assessed for 
viability at 48 hours post-treatment. 
 
























P a re n t C e ll
T M Z -R  40 M
T M Z -R  80 M
T M Z -R  160 M
C e ll V ia b ility  (T r y p h a n  B lu e  E x c lu s io n )
L N 2 2 9  &  T M Z -R  v a r ia n ts
**




3.2.5. Temozolomide-resistant LN229 human glioblastoma cells do not 
survive the high-dose radiation treatment 
As the previous findings in Section 3.2.4 showed TMZ-R cells acquire 
partial resistance to low dose radiation (up to 10 Gy), it would be interesting to 
see the effects of high-dose radiation on the LN229 TMZ-R cell panel, in 
comparison to the LN229 parent cells. The results showed that under such 
circumstances, the cells succumbed to the high-dose radiotherapy (HDRT) of 
60 Gy routinely used in the clinical setting. It was also noted that the LN229 
TMZ-R cells did display more resistance to the treatment effect in the initial 
stages. However, when the cells were harvested at Days 3, 7 and 10 after 
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completion of treatment, the number of viable cells became increasingly 
negligible. (See Figure 19). The findings in this context highlighted a couple 
of key points: firstly, LN229 TMZ-R cells in spite of their MGMT status and 
acquired chemoresistance properties, were unable to survive HDRT. Next, the 
use of HDRT as a treatment modality for GBM patients retains its 
importance182, as a majority of chemoresistant GBM cells do succumb to 
HDRT. 
 
FIGURE 19: LN229 parent and TMZ-R variant cells succumb to 
clinically relevant dose of radiation treatment (60 Gy). To achieve a final 
dose of 60 Gy to be delivered in vitro, the Biological Effective Dose (BED) 
formula was applied. From the BED, the required IR dose for the 
experiment was calculated to be 30 Gy. This was delivered over 3 
fractions at 10 Gy per day to the cells. 
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3.3. Discussion and conclusions  
In this chapter, there was derivation of therapeutically resistant GBM 
subpopulations (i.e. LN229 TMZ-R variants. 40 M, 80 M and 160 M) that 
expressed MGMT, a gene well-associated with TMZ-resistance in the clinical 
setting. The LN229 TMZ-R variant cells, in particular LN229 TMZ-R 80 M 
and 160 M also demonstrated significant reduction in some of the MMR 
proteins.  These TMZ-R variant populations were able to maintain some of the 
aggressive hallmarks in comparison to its TMZ-sensitive, MGMT-negative 
counterpart (LN229 parent cell). The correlation of MGMT in glioma 
resistance has been paralleled in large-scale patient studies where the role of 
MGMT in glioma resistance has been shown to be clinically relevant in 
present-day practice79,183. In addition, the incremental expression of MGMT in 
a TMZ dose-dependent fashion further augments its role in TMZ resistance. 
As mentioned before, these in vitro induced chemoresistance models have 
been previously reproduced by other publications184 to understand drug-related 
mechanisms in gliomas. However, this project included the novel use of 
HDRT to examine therapeutic resistance further, especially so in a clinically 
relevant setting. Furthermore, the subsequent results from the IR-related 
experiments demonstrated that LN229 TMZ-R subpopulations examined here 
were unable to sustain cell viability in the face of HDRT, in spite of their 
acquired chemoresistance. Thus, from these findings, it was surmised that yet 
another probable therapeutically resistant subpopulation is important in GBM 
tumours, based on current disease understanding. As discussed in Chapter 1.2, 
glioma stem cells (GSCs) have been previously implicated in chemo- and 
radiation resistance. Therefore, in the following chapter, GSCs were 
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A glioma ‘stem cell-like’ population in LN229 
human glioblastoma cells demonstrates therapeutic 

















A GLIOMA ‘STEM CELL-LIKE’ POPULATION IN LN229 HUMAN 
GLIOBLASTOMA CELLS DEMONSTRATES THERAPEUTIC 
RESISTANCE TO TEMOZOLOMIDE AND HIGH-DOSE IONIZING 
RADIATION 
4.1 Introduction 
The human brain, for many years previously thought to be a static, 
fully-differentiated organ, is now considered to be a dynamic environment 
driven by multiple neuronal and glial progenitor-cell populations66. As 
previously discussed, recent studies have suggested a population of GSCs with 
the capacity to repopulate tumours and mediate chemo- and radiation 
resistance. This unique subpopulation is generally characterized by low rates 
of division and proliferation, hence conferring resistance to conventional 
chemotherapy and radiation treatment that target actively cycling cells185,186. 
Putting it all together, the presence of this GSC subpopulation seems to be 
especially applicable in GBM where tumour recurrence is a clinical reality.  
 
As a whole, the GSC concept whereby an aberrant stem cell-like 
subpopulation is a sole perpetrator of therapeutic resistance in GBM is indeed 
tempting. However, a note of caution before we proceed: the existence of 
GSCs and their role in tumorigenesis is not universally accepted by all, and 
several aspects of this model remain controversial136. For instance, as neural 
stem cells and their progenitors share features similar to GSCs, there is a 
tendency to interpret lineage derivation of GSCs from NSCs or their 
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progenitor cells. One should note that it is still conceivable that more 
differentiated cells can, through multiple mutagenic events, acquire self-
renewal characteristics reminiscent of GSCs187. However, despite the ongoing 
polemics surrounding their origins, their existence and contribution to 
therapeutic resistance is still highly accepted.  
 
This chapter will attempt to describe in detail, experiences in the 
development of a ‘GSC-like’ population, establishment of its phenotype and 
















4.2.1. A ‘GSC-like’ population in LN229 human glioblastoma cells form 
neurospheres and express pluripotency markers 
Glioblastoma-derived stem cell-like spheroid cultures is an acceptable 
method used to study stem cell-like behaviour and tumour biology135. Such 
‘GSC-like’ cells have been reproducibly reported to display increased 
tumorigenicity and resistance to therapeutics in both in vitro and in 
vivomodels188. Thus by inference, this suggests that isolating this population 
will generate a highly potent population of tumour-initiating cells that can be 
used to study therapeutic resistance90,189. In this field, a range of different 
techniques has been described to isolate and culture cancer stem cells190-193. A 
common in vitro method is the neurosphere assay, where populations of 
‘GSC-like’ cells are able to continually divide and form multipotent, clonal 
neurospheres135,189 when cultured in the presence of EGF and bFGF under 
serum-free conditions194.  This approach is built on the foundation that neural 
stem cells were originally characterized and identified by their growth as 
neurospheres in a minimal medium containing growth factors195,196. 
Furthermore, the derivation of such a population from glioblastoma cell lines, 
including LN229, has been previously described in the literature197. In this 
setup, the morphology of LN229 parent cells was observed to change from an 
adherent population to a more spheroid-like one over a period of 12 to 24 





FIGURE 20: Representative photograph of LN229-derived neurospheres 
after prolonged culture in serum-free media with mitogens. 
 
 
At present, there is still an overall lack of standardization regarding the 
assessment of this so-called “stemness” phenomenon114,198,199. During the 
early works on GSCs, CD133 was proposed as a marker for brain tumour-
initiating cells.  With the insight of new knowledge, researchers have come to 
realise that using CD133 as a definitive marker is too restrictive. Furthermore, 
there are now publications that demonstrate CD133-negative cells are too, 
capable of self-renewal and instigate tumours200,201. In order for this project 
methods to remain consistent with current literature, a panel of commonly-
used neural stem cell developmental markers to profile our LN229 ‘GSC-like’ 







Next, the cells were subjected to mRNA analysis to examine if these 
LN229-derived neurospheres were able to demonstrate gene expression 
changes in the list of known neural stem cell pluripotency markers (See 
Figure 21). The mRNA results were achieved using microarray, followed by 
individual validation using RT-qPCR. (See Figures 22A and 22B). Following 
that, the LN229 ‘GSC-like’ cells that showed higher mRNA expression of 
neural stem cell markers in comparison to LN229 parent cells were checked 
for protein expression using immunoblotting. (See Figure 23A and 23B).  The 
results demonstrated significant increases in relative foldchange of MSI-1, 
SOX9, SOX2 and FABP7 mRNA expressions in LN229 ‘GSC-like’ cells. 
Most GBM tumours have been found to contain considerable number of cells 
expressing the markers Musashi-1 (MSI-1) and Sex determining region Y-box 
2 (SOX2)202,203, and the increase in their expressions has been shown to be 
prognostic of decreased overall survival for glioma patients204,205. In addition, 
the transcription factor Sex determining region Y-box 9 (SOX9) is known to 
play an important role in the development and differentiation of multiple cell 
lineages. In malignant gliomas, the overexpression of SOX9 has been 
associated with poorer clinical outcome of patients206. Also, the fatty acid 
binding protein 7 (FABP7) from the fatty acid binding (FABP) family, is 
known to be abundant in the foetal brain, and its function includes the 
development of brain cortical layers207,208. Higher expression of FABP7 has 







FIGURE 21: Schematic diagram of some of the commonly cited neural 




(Note: the list here is not exhaustive. For the purposes of this project, the 



















FIGURE 22: A. Microarray (Illumina HT-12 v4) heatmap of neural stem 
cell markers (from FIGURE 21) in LN229 ‘GSC-like’ population 
compared to LN229 parent cells. Parent 1, 2, 3  and GSC-like 1, 2, 3 
represent biological triplicates per cell type, respectively.  B. Validation of 
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FIGURE 23: A. Immunoblotting results of neural stem cell markers in 
LN229 ‘GSC-like’ cells. B. Densitometry quantification results of the 
















4.2.2. ‘GSC-like’ LN229 cells are able to form colonies in an anchorage-
independent environment 
The soft agar assay for colony formation is considered one of the most 
stringent assays for detecting malignant transformation of cells. In this setup, 
the aim was to examine the behaviour of cells that undergo in vitro 
transformation, where phenotypic changes such as anchorage independence 
and loss of contact inhibition were observed. (See Figure 24). This system is 
accepted to be a good predictor of in vivo carcinogenesis209,210.  Concordantly, 
the successful use of this assay in LN229-derived neurospheres was previously 
described by Wang et al 2012211. 
 
FIGURE 24: Soft agar colony forming assay for LN229 ‘GSC-like’ cells. 
Colonies were quantified on Day 14 post-plating. On Day 14, LN229 





4.2.3. ‘GSC-like’ LN229 cells demonstrate temozolomide resistance 
It was observed that LN229 ‘GSC-like’ cells remained more viable 
when treated with incremental doses of TMZ for 72 hours when compared to 
LN229 parent cells. (See Figure 25A). In addition, when LN229 ‘GSC-like’ 
cells were subjected to regular doses of TMZ (34 M) over the course of 10 
days, these cells continued to survive. As described in Chapter 2.1.2, the in 
vitro TMZ dose of 34 M was calculated to reflect the peak concentration of 
TMZ reached in patient glioma tissues from clinical studies139. Similarly, in 
this second experiment, LN229 ‘GSC-like’ cells remained viable in contrast to 
LN229 parent cells. (See Figure 25B). These findings were consistent with 
the notion whereby GSC populations are known to be resistant to 
chemotherapy86,170,212-214, and most likely to be responsible for tumour 
chemoresistance. This is in the context of their capacity for unlimited self-
















FIGURE 25: A. Cell viability assay of LN229 ‘GSC-like’ cells subjected to 
to a single doses of TMZ for 72 hours in incremental concentrations (0, 25, 
50, 100, 200, 400 800 M)216. [sl2]DMSO treatment was used for the vehicle 
control. B. Cell viability assay of LN229 ‘GSC-like’ cells and parent cells 
treated with regular doses of TMZ 34 M over the course of 10 days. 
DMSO treatment was used for the vehicle control.[sl3] 
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These findings also demonstrated an interesting point: LN229 ‘GSC-
like’ cells, despite being TMZ-resistant, did not express MGMT, unlike the 
previous LN229 TMZ-R cells, 40 M, 80 M and 160 M as described in 
Chapter 3. This is contrary to the expectation will be that LN229 ‘GSC-like’ 
cells may express MGMT, especially in the context of TMZ resistance177,217. 
Of noteworthy mention, Blough et al 2010’s study found that their panel of 
unmethylated MGMT promoter GSC-like lines displayed at times 
unpredictable responses to TMZ170. Here, the results indicate that LN229 
‘GSC-like’ cells do not express the same GBM chemoresistance markers as 
the LN229 TMZ-R panel. (See Table 8). This is shown in our microarray data 
(See Figure 25A). These include the MMR-related genes (MSH3, MSH6 and 
PMS1), ABC-transporter gene family members (ABCC3, ABCA3), other 
reported genes in the literature such as those involved in the cell cycle (TP53 
and RB1), and base excision repair (APEX1).Some of these genes were 
validated using RT-qPCR (See Figure 25B). Given that GBM biology is 
complex, it is thus not inconceivable that other mechanisms can be driving the 
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FIGURE 26: A. Microarray (Illumina HT-12 v4) heatmap data of 
common chemoresistance markers. Parent 1, 2, 3  and GSC-like 1, 2, 3 
represent biological triplicates per cell type, respectively. B. RT-qPCR 
validation of genes from microarray data 
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4.2.4. ‘GSC-like’ LN229 cells demonstrate radioresistance and continue to 
proliferate in the presence of ionizing radiation 
In this experiment, the effects of both low (2 to 10 Gy) and high-dose 
radiation (60 Gy) in LN229 ‘GSC-like’ cells were observed. The use of 60 Gy 
in this experiment was as previously described (See Chapter 2.7) and carried 
out in the LN229 TMZ-R cell panel (See Chapter 3.2.5). The results in this 
setup demonstrated 2 novel findings in comparison to those found in the 
LN229 TMZ-R cell panel: firstly, LN229 ‘GSC-like’ cells were able to remain 
viable under the stresses of IR. This is in contrast to LN229 parent cells, 
whereby they were sensitive to the same IR doses. (See Figure 27A). 
Furthermore, IR treatment was noted to be associated with increased 
proliferation of LN229 ‘GSC-like’ cells, as compared to their LN229 ‘GSC-
like’ untreated controls. (See Figure 27B). 
 
With regards to the first finding, the property of radioresistance in 
cancer stem cells, including GBMs, is not entirely novel. Previous work by 
Bao et al 2006 had demonstrated that radiation resistance is mediated from 
GSCs within the GBM mass via preferential activation of DNA damage 
checkpoint response188. A parallel observation was seen in breast cancer cells, 
where cells maintained in spheroids were more radioresistant, demonstrating 
an absolute difference in mean survival fraction of approximately 20% when 
subjected to 2 Gy IR treatment218. There are also recent in vitro studies 
suggesting that therapeutic stressors, including IR, can induce a cancer stem-
like phenotype in differentiated tumour cells—an indication of stem cell 
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plasticity as a plausible mechanism for survival219. In contrast, literature 
supporting the results from this second finding is scarce. However, a paper by 
Kil et al 2012 noted the significant increase of secreted VEGF after in vitro 
GBM cells were subjected to low-dose IR220. Although this study did not 
include cell proliferation as an endpoint, its outcomes do insinuate the 
likelihood of GBM cells secreting growth factors as a response to IR, hence 


























FIGURE 27: A. Cell viability assay of LN229 ‘GSC-like’ cells when 
subjected to single incremental doses of IR (0, 2, 4, 8, 10 Gy). B. Cell 
viability assay of LN229 ‘GSC-like’ cells treated with HDRT (60 Gy). The 
starting number of cells per line was 100k. LN229 parent cells were used 
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4.2.5. ‘GSC-like’ LN229 cells survive clinically relevant chemo-radiation 
treatments used for glioblastoma tumours 
After subjecting LN229 ‘GSC-like’ cells to clinically relevant 
treatment, the cells continued to remain viable. However, it was also noted 
that under different treatment conditions, they displayed variable growth rates. 
For instance, when subjected to prolonged TMZ alone, the cell numbers were 
noted to be less in comparison to DMSO control. (See Figure 28A).Our 
results demonstrating a decrease in proliferation in LN229 ‘GSC-like’ cells 
concurs with a previous study by Blough et al 2010170. There, and in other 
similar reports, authors had found that some GSC populations can be 
susceptible to the effects of TMZ170,221.  
 
 Furthermore, when treated with RT alone, the cell numbers were 
exponentially higher compared to DMSO control. However, when treated with 
simultaneous TMZ and RT, despite continued growth, the cell numbers were 
still less than the cells which underwent the RT treatment arm only. From 
these findings, it was concluded that although TMZ as a monotherapeutic drug 
does not kill LN229 ‘GSC-like’ cells, it has some effect in reducing its growth 
numbers. In addition, TMZ when combined with RT, is able to slow down 
overall tumour cell growth in comparison to RT alone. (See Figure 28B). 
Importantly, these results are in concordance with real-life patient outcomes, 




FIGURE 28: A. Cell viability results of LN229 ‘GSC-like’ cells after 
treatment with TMZ (34 M) and HDRT (60 Gy) as per clinically 
relevant treatment based on the ‘Stupp Protocol’30. LN229 parent cells 
were used in the same experimental setup for comparison. The starting 
number of cells per line was 100k. B. Cell viability results demonstrating 
effects of TMZ (34 M) on LN229 ‘GSC-like’ cells when administered 
with, and without HDRT (60 Gy). LN229 ‘GSC-like’ cells in DMSO were 
used as the control for TMZ treatment. 
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4.3. Discussion and conclusions 
The current perception is that most malignant tumours, such as GBM, 
are postulated to originate from a subpopulation within themselves. Here, 
these so-called ‘GSCs’ are thought to possess an immature phenotype, with 
chemo-radiation resistance capacity as one of its key characteristics34,215. 
Accordingly, in this chapter, the existence of such a subpopulation was 
explored, with methods reproduced from scientific literature and subjected 
these cells to clinically relevant treatment using TMZ (34 M) and HDRT (60 
Gy). So far, the observations correlated with current concepts underlying 
therapeutic resistance, and also remain in congruency with our primary 
hypothesis, whereby a subpopulation of GBM cells would be resistant to 
standard chemo-radiation therapy. These findings demonstrated that LN229 
‘GSC-like’ cells had shown to be remarkably resistant to radio- and 
chemotherapies. Hence, it was postulated that their resistance property would 
likely concurs with genomic and proteomic profiles distinct from their non-
GSC population, as previously suggested in the literature7. As clearly laid-out, 
the understanding of chemo-radiation resistance of GSCs, and their persistent 
propagation in the face of treatment may hold the answer to improve curability 
for this disease. Drawing from these results, the priority interest will be to 
know if the properties underlying pro-survival effect of LN229 ‘GSC-like’ 
cells when treated with TMZ, RT or concomitantly, are synergistic or 
independent. Therefore, for the following chapters, the aim is to investigate 
the potential involvement of miRNAs as the underlying contribution towards 













A distinct group of miRNAs was observed to have 
expression changes in LN229 ‘GSC-like’ cells 
induced by clinically relevant treatment 
 
‘You have to learn the rules of the game. And then you have to play better than 
anyone else.’ 















A DISTINCT GROUP OF MIRNAS WERE OBSERVED TO HAVE 
EXPRESSION CHANGES IN LN229 ‘GSC-LIKE’ CELLS INDUCED 
BY CLINICALLY RELEVANT TREATMENT 
5.1. Introduction  
In this chapter, the aim was to test the project’s secondary hypothesis 
(i.e. the surviving LN229 ‘GSC-like’ cells are a molecularly distinct 
subpopulation), and to use a miRNA-centered approach to fulfill the 
objectives.  
 
Based on current knowledge, one is now aware that miRNAs are 
important regulators of mammalian stem cell division and development223. 
Similarly, for neural stem cells, the evidence seem to suggest that miRNAs are 
important for stem cell differentiation and proliferation224. In a parallel context, 
GSCs in Kim et al 2011’s previously mentioned taxonomy study (Chapter 1) 
demonstrated that miRNAs determine GBM subclasses through their abilities 
to regulate developmental growth and differentiation programs in transformed 
neural precursor cells104. This aspect of their involvement in neural precursor 
cells is now apparent and applicable in this project. This chapter attempts to 
provide an in-depth discussion of the miRNA changes observed in LN229 
‘GSC-like’ cells after clinically relevant treatment, and follow through with a 
discussion on the relevance of the miRNAs that were used to map for mRNA 
targets. Furthermore, it is common knowledge that mammalian miRNAs 
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perform gene regulatory roles by base-pairing to mRNAs to specify post-
transcriptional repression of these messages225. 
 
5.2 Results 
5.2.1. Clusters of miRNAs were observed to have significant expression 
changes during clinically relevant treatment 
It was observed that LN229 ‘GSC-like’ cells demonstrated 
significant miRNA expression changes during the course of 
independent treatment(s) with TMZ (34 M), HDRT (60 Gy) or, 
combinatorial TMZ (34 M) and HDRT (60 Gy), in comparison to the 
LN229 ‘GSC-like’ DMSO control cells. Given the diverse roles of 
miRNAs in the regulation of different cell functions, including survival, 
these patterns of treatment-induced changes in miRNA expression 
were not unexpected. During the analysis of the miRNA data, 
particular attention was given to the miRNAs that were simultaneously 
downregulated in the presence of TMZ, RT and combined TMZ and 
RT. (See Figure 29A). The reasons for this selection were firstly, 
miRNAs reported to be suppressed in brain tumours are usually 
involved in the regulation of functions which may benefit for cancer 
growth and propagation38. Furthermore, previous analyses of miRNA 
expression in several human cancers had shown a general 
downregulation trend for miRNAs in tumours, in comparison to 
normal tissue counterparts226. This is postulated to be related to 
presumed defects in the molecular machinery used for miRNA 
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processing224, such as defects in Drosha-mediated pri-miRNA cleavage 
227. Corroboratively, the observation that a global reduction of miRNA 
expression, biogenesis and loss of miRNA function disrupts stem cell 
differentiation, suggests that functional miRNA loss promotes glioma 
formation by arresting GSC differentiation224. Next, owing to the 
inverse relationship in the miRNA-mRNA connection, the 
downregulation of a miRNA implies that the increase in expression of 
its related mRNA may be by either via direct or indirect regulation. 
Moreover, the search for upregulated genes that perpetuate 
oncogenicity is cogent for potential biomarkers and, or the 
development of targeted molecular therapeutics. Following this, as 
previously mentioned in Chapter 4, the project’s aims include the 
interest to know if the molecular targets affected by individual 
monotherapy (i.e. TMZ or HDRT) versus combinatorial TMZ and 
HDRT are similar in all 3 treatment arms. Finally, to be more stringent, 
the miRNAs of interest were part of the GBM miRNA subtyping 
taxonomy list reported by Kim et al 2011, as their selected miRNAs 
stratified with patient survival104. As a result, miR-125a-3p, miR-629-
5p and miR-19b-3p were found to fit into the criterion established. 
Interestingly, when matched against the miRNA-based subtyping 
taxonomy, their pre-miRs were observed to be downregulated in the 
subtypes associated with lower median survival and poorer response to 






FIGURE 29: A. Heatmap of RT-qPCR of miRNA profiling panel. The 
regions boxed in yellow highlight the clusters of miRNA changes. B. The 3 
selected miRNAs were chosen from the raw data using the criteria, where 
the miRNA of interest is consistently downregulated in all 3 arms of 
treatment: TMZ only, RT only and combinatorial TMZ and RT, in 























Background of downregulated miRNAs: 
miR-125a-3p 
Downregulation of miR-125a-3p has been previously noted by Jiang et 
al 2010 in non-small cell lung carcinoma, and is associated with lymph node 
metastasis228. This observation has also been reported in gastric cancer where 
a lower expression of miR-125a-3p is associated with enhanced malignant 
potential and tumour dissemination in a matched patient cohort study229. 
Correspondingly, there are studies that have observed downregulation of its 
mature counterpart, miR-125a-5p in medulloblastomas230 and other visceral 
tumours231,232. In addition, its pre-miR 125a has been previously reported to be 
downregulated in gliomas in comparison to normal brain tissue38. However, 
the specific mRNA targets and pathways regulated by miR-125a-3p remains 
uncertain at this stage. Nonetheless, putting all current evidence together, there 
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In a similar context, the pre-miRNA 629 has been previously observed 
to be in a cluster of downregulated miRNAs for breast cancer with metastases 
versus breast cancer without metastases233. With the insight of translational 
work in miRNAs, we are now aware that the expression of distinct miRNAs 
seem to be associated with the efficacy of therapeutic interventions, such as 
radiation therapy234,235. Interestingly, a study by Niemoeller et al 2011 looking 
at miRNA expression profiles in a panel of different cancer cell lines noted 
that the human glioblastoma cell line LN229, (which was used in this study) 
expressed lower miR-625 levels post-irradiation treatment236. 
 
miR-19b-3p 
Amongst all the 3 selected miRNAs, miR-19b-3p has the least known 
function in glioma biology at this point in time. This miRNA belongs to the 
mir-17-92 miRNA cluster; hence any reports of gene regulation usually 
involves the whole cluster. This is because unlike classic protein-coding 
oncogenes, whereby 1 transcript usually gives rise to 1 protein product, the 
mir-17-92 cluster produces a single cistronic primary transcript that can yield 
6 individually mature miRNAs. Subsequently, the distinct miRNA sequence 
of the mir-17-92 components dictates the specificity of their target regulation, 
in order to eventually determine individual functional specificity225. As an 
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individual entity, the miR-19b has been implicated in immunological diseases, 
such as rheumatoid arthritis237,238. 
 
5.2.2. Downregulation of miR-125a-3p, miR-625-3p and miR-19b-5p 
correspond with upregulation of RFX1 and FLVCR2 genes in LN229 
‘GSC-like’ cells 
The 3 miRNAs (miR-125a-3p, miR-629-5p and miR-19b-3p) were 
input into miRror 2.0 target prediction software150 to identify mRNA targets. 
As previously mentioned, the programme analysis is based on a ‘many-to-one’ 
approach in which a set of input miRNAs is optimized for a minimal set of 
gene targets that are known to be maximally regulated by this set150.These 
results were matched against upregulated mRNA in the microarray data set of 
the same cell populations subjected to similar 3 treatment arms: TMZ only, 
RT only and combinatorial TMZ and RT, in comparison to DMSO control. 
There were 19 predicted genes in the list identified as mRNA targets using 
miRror2.0 target prediction software that matched the upregulated mRNAs 
from our microarray data. (See Figure 30). Next, each individual gene was 
validated with RT-qPCR. Out of all the genes, it was found that RFX1 and 
FLVCR2 were correspondingly upregulated in the same LN229 ‘GSC-like’ 
cells that were treated with TMZ (34 M), HDRT (60 Gy) or, combinatorial 





FIGURE 30: Schematic diagram demonstrating workflow of miRNA-
mRNA target prediction using miRor 2.0. The list of predicted mRNA 
targets was mapped to the microarray data from the same panel of LN229 
‘GSC-like’ cells which have undergone the same 3 treatment arms: TMZ 




FIGURE 31: RT-qPCR results validating the upregulation of RFX1 and 
FLVCR2 in LN229 ‘GSC-like’ cells 48 hours after treatment with TMZ 
(34 M) and, or HDRT (60 Gy). 
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Background of upregulated mRNAs that are potential miRNA targets: 
Regulatory factor X1 (RFX1) 
The RFX gene family transcription factors were first reported in 
mammals as the regulatory factor that binds to a conserved cis-regulatory 
element called the X-box motif in 1988239. In this group, RFX1 was 
characterized as a candidate major histocompatibility complex (MHC) class II 
promoter binding protein240. Subsequent studies on the RFX family 
demonstrated that they are homodimeric and heterodimeric DNA-binding 
proteins241 with critical roles in mammalian development242. In humans, RFX1 
is highly expressed in the cerebral cortex243. This transcription factor also 
appears to be expressed in the other tissue types, such as the heart, eye and 
testis242. Other studies in human disease found RFX1 to be a functional trans 
activator of the hepatitis B virus enhancer244.  
 
At present, the knowledge of detailed mechanisms underlying RFX1 
and gliomas remain limited. However, interestingly, there have been some 
reports that RFX1 may have a tumour suppressive role in gliomas. For 
example, Feng et al 2014 demonstrated that RFX1 directly downregulates 
CD44, a stem cell marker highly expressed in both normal brain245 and in 
glioblastoma, especially of the mesenchymal subtype93. Broadly speaking, 
CD44 is a glycoprotein transmembrane receptor that is known to function as a 
cell adhesion and intracellular signaling molecule246. CD44-mediated adhesion 
is thought to have a role in maintaining the stem cell niche247 and its overall 
expression is utilized for enrichment of GSCs248. Next, in Hsu et al 2010’s 
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work, RFX1 was identified as a transcription suppressor of the human 
fibroblast growth factor 1 (FGF1) gene promoter249. The FGF1 gene has 4 
known upstream untranslated exons250-252, and they play roles in neurogenesis, 
cell growth and proliferation249. In this group, the exon FGF-1B is the major 
transcript within the human brain251. More significantly, in the context of the 
project’s disease of interest, it has been shown that most malignant gliomas 
express FGF1 utilizing the 1B promoter. The study probing the association 
between RFX1 and FGF1 suggests that RFX1 negatively regulates GSC self-
renewal via binding to the 18-bp cis-element in the FGF-1B promoter249, to 
modulate overall FGF1 gene expression. 
 
Feline leukaemia virus subgroup C cellular receptor family, member 2 
(FLVCR2) 
FLVCR2 is a cell surface membrane protein that belongs the major 
facilitator family (MFS), the largest and most diverse superfamily of 
membrane transporters253,254. Although its role in GBM has not been reported, 
germline mutations in FLVCR2 has been recently shown to be associated with 
Fowler Syndrome255-258. Fowler Syndrome, also known as proliferative 
vasculopathy and hydranencephaly-hydrocephaly (PVHH), is a proliferative 
vascular disorder of the brain259. Essentially, this is a rare but lethal prenatal 
disorder where there is glomeruloid vasculopathy throughout the CNS, with 
varying degrees of calcification and necrosis in both white and grey matter258. 
Following this, Duffy et al 2010’s work reinforced the association between 
FLVCR2 and Fowler Syndrome by firstly, functionally demonstrating that 
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FLVCR2 binds to and imports haem. Next, they also showed that FLVCR2 is 
abundantly expressed in a large range of normal human tissues, especially in 
the brain260. Therefore, given its important physiological role and strong 
presence in the brain, it is not implausible that mutations involving FLVCR2 


















5.2.3. Independent overexpression of miR-125a-3p, miR-625-3p and miR-
19b-5p reduces LN229 ‘GSC-like’ cell viability in the presence of 
clinically relevant treatment 
In order to test the functionality of the 3 selected miRNAs, the miRNA 
mimics for miR-125a-3p, miR-629-5p and miR-19b-3p to independently 
overexpress the LN229 ‘GSC-like’ cells were used. Post-transfection, the cells 
were subjected to the same clinically relevant treatments: TMZ (34 M), 
HDRT (60 Gy) or, combinatorial TMZ (34 uM) and HDRT (60 Gy), as 
described in Chapter 4.2.5. (See Figures 32A and 32B). The results 
demonstrated the following: firstly, after the cells were transfected, there was 
no observation of any significant difference in the cell numbers in the DMSO-
treatment control arm. Next, the transfected cells overexpressing each of the 
miRNAs were found to be more susceptible to all 3 treatment arms in the 
experimental setup. Overall, a similar trend was noted across all the 3 selected 
miRNAs, whereby higher expression of each miRNA conferred lower cell 










FIGURE 32: A. Cell viability assay of LN229 ‘GSC-like’ cells transfected 
with miRNA mimics and treated with TMZ (34 M), HDRT (60 Gy) or, 
combinatorial TMZ (34 M) and HDRT (60 Gy).The cells were harvested 
48 hours after completion of treatment. B. RT-qPCR results 
demonstrating transfection efficiency of the miRNA mimics used. miR-16 
was used as an internal control for this experiment. 
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5.2.4. Independent overexpression of miR-125a-3p, miR-625-3p and miR-
19b-5p in LN229 ‘GSC-like’ cells lead to corresponding downregulation 
of RFX1 and FLVCR2 genes in the presence of clinically relevant 
treatment 
Following the previous experiment (5.2.3), the next step was to seek 
the mRNA levels of RFX1 and FLVCR2 in LN229 ‘GSC-like’ cells that were 
independently transfected with the miRNA mimics. The findings 
demonstrated the gene expression of RFX1 and FLVCR2 in the same cells to 
be reduced in the presence of clinically relevant treatment. (See Figures 33A 
and 33B). Collectively, these results confirmed a reliable association between 
our 3 selected miRNAs and the 2 predicted mRNA targets, thus strengthening 



















FIGURE 33: RT-qPCR results showing expression of RFX1 and FLVCR2 
in LN229 ‘GSC-like’ cells that were transfected with miRNA mimics and 
treated with TMZ (34 M), HDRT (60 Gy) or, combinatorial TMZ (34 
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* p-value <0.05 
** p-value <0.01 
* p-value <0.05 
** p-value <0.01 
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5.3. Discussion and conclusions 
In this chapter, the following objectives were achieved: firstly, the 
demonstration of a feasible approach in the use of dysregulated miRNAs to 
map target mRNAs in the roles of resistance. The miRNA-derived effects of 
chemo- and radiation treatment on LN229 ‘GSC-like’ cells, and established 
their miRNA-mRNA relationships using a miRNA transfection approach was 
examined. At this point in time, there remains paucity of knowledge 
underlying each of these miRNAs, especially in their independent, or 
combinatorial roles in GBM prognosis. [sl5] Following this, a well-accepted 
miRNA-mRNA target prediction software programme (miRror 2.0) to provide 
results that seek a consensus from a variety of databases was utilised. As 
reflected in current research consensus, many still grapple with inconsistencies 
among many miRNA-targets. This reflects that a large portion of false-
positives remains associated with each available resource261,262. These 
inconsistent findings were encountered first-hand during the validation 
exercise of the 19 predicted mRNA targets, where only 2 of the genes were 
consistently upregulated. Nevertheless, this approach acknowledges the 
potential of miRNA-target prediction softwares, and anticipate their increasing 
importance in the near future. Moving forward, based upon the overall 





















Gene knockdown of RFX1 and FLVCR2 in LN229 
‘GSC-like’ cells confer sensitivity to clinically 
relevant treatment 
 
‘Now faith is confidence in what we hope for and assurance about what we do 
not see.’ 











GENE KNOCKDOWN OF RFX1 AND FLVCR2 IN LN229 ‘GSC-LIKE’ 
CELLS CONFER SENSITIVITY TO CLINICALLY RELEVANT 
TREATMENTS 
6.1 Introduction 
Due to the complex nature of GBM, establishing key oncogenes for 
potential therapeutic targets has been difficult263. However, with the advent of 
better miRNA understanding, their functions in gene modulation and the input 
of bioinformatics, we are now more appreciative of how miRNA-mRNA 
mapping can contribute to the identification of therapeutic targets for GBM. 
 
In the previous chapter (Chapter 5), based on miRNA-mRNA target 
prediction, the findings demonstrated consistent upregulation of RFX1 and 
FLVCR2 genes when miR-125a-3p, miR-629-5p and miR-19-3p were 
downregulated. Of interest, the opposite trend was observed when these 3 
implicated miRNAs were overexpressed. Taken together, the 2 genes of 
interest, RFX1 and FLVCR2 show potential as oncogenes in LN229 ‘GSC-
like’ cells. As the results suggest the 3 miRNAs are capable of independently 
regulating RFX1 and FLVCR2 expression, the search for a possible consensus 
motif was trialled using 2 well-published online programmes, MBStar264 and 
rna22 (version 1.0)265. However, based on these 2 current programmes, there 
was no consensus motif thus far, for these 2 transcription factors, matching to 
the 3 miRNAs of interest. Owing to the reality that miRNA-related biology in 
disease remains relatively novel, there is a definite possibility that newer, 
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improved versions of target prediction programmes in the near future will be 
able to identify such consensus motifs. [sl6] Moving forward, the roles of RFX1 
and FLVCR2 were tested in LN229 ‘GSC-like’ cells by using a siRNA 
knockdown approach, and the transfected cells were subjected to clinically 
relevant treatment. Furthermore, to ascertain if the candidates genes are 
clinically relevant, a bioinformatics approach was employed to assess the 
median expression level of each gene against patient survival, using 2 large 
clinical glioma databases: REMBRANDT94and Gravendeel151. 
 
6.2. Results 
6.2.1. Independent siRNA knockdown of RFX1 and FLVCR2 in LN229 
‘GSC-like’ cells reduce cell viability during clinically relevant treatment  
 
In this experimental setup, the independent effects of RFX1 and 
FLVCR2 gene knockdown in LN229 ‘GSC-like’ cells were investigated. The 
results indicated that in the presence of gene silencing, LN229 ‘GSC-like’ 
cells demonstrated similar trends in cell viability reduction when subjected to 
clinically relevant treatment. Post-transfection, LN229 ‘GSC-like cells were 
treated with one of the following treatment arms: TMZ (34 M) only, RT (60 
Gy) only, or combined TMZ (34 M) and RT (60 Gy). The results of 
individual treatments were compared to a DMSO control.  (See Figure 34A). 
In order to confirm the genes of interests were silenced, RT-qPCR was 
performed on the harvested cells. (See Figure 34B). These findings help to 
confirm the project’s previous miRNA-derived data (Chapter 5), and reinstate 
the potential roles of RFX1 and FLVCR2 in tumour cell survival. As the 
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current knowledge of both RFX1 and FLVCR2 is limited at this stage, the next 





















FIGURE 34: A. Cell viability assay of siRNA-transfected LN229 ‘GSC-
like’ cells that were treated with TMZ (34 M), HDRT (60 Gy) or, 
combinatorial TMZ (34 M) and HDRT (60 Gy). B. RT-qPCR results 
demonstrating transfection efficiency of RFX1 and FLVCR2 at 
transcriptional level. 
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6.2.2. Higher expression of RFX1 and FLVCR2 demonstrate poorer 
overall survival in patient glioma databases (with assistance of Edwin 
Sandanaraj, Senior Research Fellow in bioformatics at NNI) 
Regulatory factor X1 (RFX1) 
In both REMBRANDT94 and Gravendeel151 databases, RFX1 
demonstrated similar trends in its gene expression and overall survival. For 
gene expression, RFX1 was observed to be significantly elevated in the higher 
grade gliomas, especially GBM (See Figure 35A). Also, it was noted that 
patients with higher RFX1 expression had poorer overall survival. (See Figure 
33B). However, when data from each database was subjected to multivariate 
Cox-regression analysis, the results were varied. RFX1 gene expression was 
analysed against 2 known prognostic factors in glioma tumours: age and WHO 
grading. In the REMBRANDT dataset, RFX1 showed that it is an independent 
prognostic factor after accounting for age and histological grading. In contrast, 
in the Gravendeel analysis, RFX1 showed up as an alternative prognostic 
indicator instead. (See Figure 35C). Nevertheless, putting it all together, our 











FIGURE 35: A. Gene expression of RFX1 in REMBRANDT and 
Gravendeel in relation to glioma histological subtype. (NT = Non-tumour, 
AS = Astrocytoma, ODG = Oligodendroglioma, GBM = Glioblastoma, 
PCAS = Pilocyticastrocytoma, AP = Anaplastic Astrocytoma) B. Survival 
curves of glioma patients correlated with variable gene expression of 
RFX1. C. Multivariate analysis using Cox regression for RFX1 




Feline leukaemia virus subgroup C cellular receptor family, member 2 
(FLVCR2) 
In the case of FLVCR2, its gene expression, overall survival and 
multivariate Cox-regression analysis showed similar trends in both 
REMBRANDT and Gravendeel. The gene of expression of FLVCR2 was 
observed to higher in GBM, in comparison to non-tumour controls and low 
grade gliomas. (See Figure 36A). Next, we also noted that glioma patients 
with high and intermediate expression of FLVCR2 have statistically 
significant poorer overall survival, in contrast to patients who had lower 
expression. (See Figure 36B). The multivariate Cox-regression model in both 
glioma databases showed that FLVCR2 is an alternative prognostic factor after 
accounting for age and histological grading. As previously for RFX1, our 
analysis implies that the expression of FLVCR2 is correlative with poorer 
















FIGURE 36: A. Gene expression of FLVCR2 in REMBRANDT and 
Gravendeel in relation to glioma histological subtype. (NT = Non-tumour, 
AS = Astrocytoma, ODG = Oligodendroglioma, GBM = Glioblastoma, 
PCAS = Pilocytic Astrocytoma, AP = Anaplastic Astrocytoma) B. 
Survival curves of glioma patients correlated with variable gene 
expression of FLVCR2. C. Multivariate analysis using Cox regression for 




6.3. Discussion and conclusions 
Although current (albeit limited) literature suggests the role of RFX1 
as a tumour suppressor, these results indicate otherwise, especially in the 
context of clinically relevant treatment. More importantly, the oncogenicity of 
RFX1 and FLVCR2 is reinforced in 2 independent patient glioma databases, 
reinforcing the potential of their translation relevance. This aspect of the 
project highlights the importance of biomedical informatics and tools for 
validating specific genomic queries in GBM94. In this aspect, it was observed 
that high expression of RFX1 and FLVCR2 independently stratified patient 
survival. Patients with poor prognosis correlated with high gene expression 
levels, while patients with favourable prognosis demonstrated lower gene 
expression patterns. The collective clinical data not only augments the initial 
in vitro results, but also provides evidence that both genes are important 
























General discussion and future work proposal 
 
‘Doctor, I don’t’know why I am still here’. 
A glioblastoma patient, Singapore 
(Quote said at the time of last outpatient appointment when imaging showed 












Chapter 7.  
GENERAL DISCUSSION AND FUTURE WORK PROPOSAL 
7.1. Summary of project 
To recap the aims of the project:  
  Hypothesis 
1. There is a subpopulation of GBM cells that is resistant to standard 
chemo-radiation therapy. 
2. Therapeutically-resistant GBM cells are a molecularly distinct 
subpopulation whose properties are regulated by miRNAs 
  Objectives 
3. To demonstrate a subpopulation of GBM cells is resistant to chemo-
radiation therapy. 
4. To examine whether different miRNA expression underlying GBM 
heterogeneity contributes towards resistance in chemo-radiation 
therapy. 
 
 This project explored the hypothesis for therapeutic resistance in GBM 
using an in vitro approach. Based on the acknowledgement that elusiveness to 
treatment is due to tumoral heterogeneity in GBM tumours, appropriate 
cellular models were developed to simulate implicated subpopulations in the 
presence of clinically relevant treatment. In the temozolomide-resistant LN229 
glioblastoma models, the significance of MGMT in chemoresistance and 
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discovered that MGMT-positive cells were able to maintain the cancer 
hallmarks of proliferation, migration and invasion as compared to the 
temozolomide-sensitive, MGMT-negative cells were uncovered. However, in 
the presence of higher doses of IR, these cells succumbed to treatment. 
Following that, the impact of clinically relevant therapeutics on a LN229 
‘GSC-like’ glioblastoma population that expressed pluripotency markers and 
displayed tumorigenic properties were explored. Not only did this particular 
population demonstrate therapeutic resistance and continued cell viability, 
they were able to demonstrate distinct miRNA changes in the presence of 
treatment. In this cluster, 3 miRNAs in particular, miR-125a-3p, miR-629-5p 
and miR-19b-3p demonstrated statistically significant downregulation in 
comparison to the control cells. Independent overexpression of these 3 
miRNAs in LN229 ‘GSC-like’ cells showed reduced cell viability in the 
presence of the same clinically relevant treatment. 
 
Next, the 3 miRNAs, miR-125a-3p, miR-629-5p and miR-19b-3p, 
were mapped to mRNA to using mirRor 2.0, a predictive miRNA-mRNA 
target analysis database. The resulting list of predict mRNA targets were 
counter-checked against mRNA microarray data from the same cell 
populations. In order to ensure the biological certainty of the target genes, 
each mRNA was individually validated with RT-qPCR. From the predicted 
mRNA list, RFX1 and FLVCR2 were found to significantly upregulated in the 
presence of these 3 downregulated miRNAs. In order confirm their functional 
meaning, independent knockdown of RFX1 and FLVCR2 was achieved using 
siRNA knockdown in LN229 ‘GSC-like’ cells. These cells were then 
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subjected to the initial clinically relevant treatment set-up. Our observations 
indicate that when RFX1 and FLVCR2 were silenced, the LN229 ‘GSC-like’ 
cells became less viable during treatment. More significantly, the oncogenic 
roles of RFX1 and FLVCR2 were further re-established in 2 independent 
patient glioma databases, REMBRANDT and Gravendeel. In both databases, 
individual higher expression of RFX1 and FLVCR2 conferred poorer survival 
in GBM patients.  
 
In summary, this project was able to establish a molecularly-distinct 
subpopulation that was therapeutically resistant against current GBM 
treatment regimen. A miRNA-based approach to look for mRNA targets of 
interest, especially in the context of resistance was utilized. The 3 miRNAs, 
miR-125a-3p, miR-629-5p and miR-19b-3p, were firstly, independently 
validated using miRNA mimics in LN229 ‘GSC-like’ cells, and subsequently 
mapped to potential mRNA targets using prediction miRNA-mRNA analysis. 
After experimentally validating these mRNA targets, RFX1 and FLVCR2 
were found to be of functional relevance (in vitro) and clinical significance for 
survival stratification (in patient glioma databases). Overall, the project 
demonstrated diverse interplays of current knowledge and key concepts 
underlying GBM therapeutic resistance—all integral parts of a common aim to 





7.2. Future work: proposed directions for a disease understanding in 
therapeutically resistant glioblastomas 
Owing to the wide scope and complexities of the disease, certain 
pitfalls faced in the scientific execution of this project are readily 
acknowledged: the approach was broad-based and the overall findings were of 
moderate depth.  Hence, the subsequent discussion proposes an outline of the 
future work to address these issues. 
 
7.2.1. Significance of RFX1 and FLVCR2 in glioblastoma 
 RFX1 and FLVCR2 are relatively new in GBM. At this point in time, 
there is little known of their exact contributions to the disease, especially for 
FLVCR2. Although there is some recent literature on RFX1 in GBM, the 
understanding of its role in this tumour remains preliminary. Based on the 
preliminary results of the 3 miRNAs and the 2 associated mRNAs, the project 
proposes to include the following imperative experiments: firstly, since all 3 
miRNAs (miR-125a-3p, miR-625-3p and miR-19b-5p) are downregulated, it 
will be interesting to observe if cell viability is even more significantly 
reduced when all 3 miRNAs mimetics are present in LN229 'GSC-like' cells. 
In addition, the use of dual silencing of both RFX1 and FLVCR2 in the same 
cell lines may demonstrate a synergistic loss of more cell viability as well in 
the presence of administered treatments.  
 
However, despite the promising results in discovering 2 potential genes 
of interest in therapeutic resistance, the following factors should also be 
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highlighted. Firstly, in this project, we used a human glioblastoma cell line 
(LN229) for the purposes of elucidating GBM’s underlying biology. 
Following this, although studies have shown that some discrete features of 
glioma biology are conserved in established glioma cell lines, we now accept 
that they possess significant differences from those found in primary 
tumours266. 
 
Moving forward, it will therefore, be imperative to establish the roles 
of RFX1 and FLVCR2 in patient-derived glioma-propagating cells both in 
vitro and in vivo, in order to decipher their mechanisms underlying therapeutic 
resistance. Here, the relevance of using glioma-propagating cells directly from 
primary tumours is important:  there is now evidence these tumour cells re-
capitulate the genomics and gene expression profiles better than those from 
established cell lines266. In addition, one is also aware that patient-derived 
glioma-propagating cells are able to form orthotopic tumours in xenograft 
mouse models267, reflecting a good simulation of brain tumour development in 
its appropriate microenvironment. Here, the next proposal is to study the 
knockdown effect of RFX1 and FLVCR2 in such glioma-propagating cells in 
vivo, followed by in-depth surveillance of possible resistance pathways to 
elucidate their mechanisms. Hence, under these circumstances, the project can 





7.2.2. Potential applications of a miRNA-centred approach in 
glioblastoma management 
Malignant gliomas are often viewed as a manifestation of multiple 
inter-connected tumour networks controlled by both intra- and extra-cellular 
events114. In pre-miRNA era, there was much difficulty in establishing the key 
connections underlying GBM biology. However, one is now aware that 
miRNA-mediated mechanisms can greatly enlighten researchers on the 
previously-deemed elusive layer of regulation in these networks. As a 
continuation of our project findings, the project proposes to study the 
mechanisms underlying therapeutic resistance in the 3 implicated miRNAs 
(miR-125a-3p, miR-629-5p and miR-19b-3p) in patient-derived glioma-
propagating cells both in vitro and in vivo, especially in the context of RFX1 
and FLVCR2. In this situation, the hypothesis is that these 3 miRNAs (miR-
125a-3p, miR-629-5p and miR-19b-3p) are likely targeting a common tumour 
suppressive pathway in GBM cells. As the mechanisms underlying the 
project’s miRNA-mRNA findings are scarce at this stage, as a starting point, 
one shall rely on the known pro-survival pathways in GBM, such as PI3K-
AKT (Phosphatidylinositol-3-Kinase and Protein Kinase B) and MAPK-ERK 
(Mitogen Activated Protein Kinase and Extracellular signal regulated Kinase) 
pathways to guide our study. Furthermore, the project’s findings also 
emphasize that there is still much to be done in the bioinformatics aspect of 
current miRNA-mRNA prediction programmes, as reflected in our results. 
Predicted targets still need to conscientiously validated by the user. 
Nevertheless, in the near future, we can anticipate miRNA research will 




In conclusion, this project explored key concepts underlying 
therapeutic resistance and used a miRNA-centred investigation in attempts to 
uncover possible gene targets associated with GBM cell survival in the face of 
clinically relevant treatment. Overall, it hopes to have laid the groundwork for 
a feasible approach to understanding this problem. 
 
As clearly demonstrated by the clinical reality and the project findings, 
the elusive nature of GBM urgently calls for efforts to implement strategies to 
improve current treatment and identify molecular markers to provide insight 
into the disease53. To emphasize this, a local study by Tham et al on 62 
patients with malignant gliomas over  a period of 10 years reported no 
significant benefit of combinatorial TMZ with RT, as compared to RT alone268. 
At this point in time, this has been the only clinical study published, involving 
malignant glioma patients in Singapore. A key point noted by the authors was 
that the use of molecular biomarkers was not a routine part of the diagnostic 
assessment. Their results concluded that the availability of such modalities 
would have helped to stratify GBM patients, in order to select patients who 
can benefit from concomitant TMZ and RT268. 
 
Clinicians and scientists are constantly struggling to undermine the 
biology of GBM. In this disease, the challenges are multiple: the biology, 
where itsinnate heterogeneity is a source of mechanistic elusiveness; the 
therapeutics, where risks of CNS and systemic complications are morbid; and 
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most of all, the human effects, where patients and their families walk in the 
path of helplessness. To bring forward improvements in GBM management, 
Hippocrates’ aphorism still holds today269:  
“Life is short, 
The art of medicine long. 
Time is fleeting, 
Experience fallible. 
Decisions difficult. 
The physician must not only be prepared to do what is right himself, but also 
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Cell ID Report 
 
Prepared by:  Sarah Low Hong Hui 
Date Prepared:  30 April 2014  
1 Sample Information 
Sample Order 1 
Sample ID LN229 
Additional ID Comments NA 
Sample Type Cell Pellet 
Estimated Cells in Pellet 1 x 106 
DNA volume (µl) NA 
DNA concentration (ng/µl) NA 
DNA quality (A260/280) NA 
Volume Solution Provided (µl) NA 
  
Operator (Processing) Tan Sili 
Date Cell Pellet Received 2014-04-15 
Date DNA Received/Extracted 2014-04-25 
175 
 
DNA volume (µl) 50 
DNA concentration (ng/µl) 193.43 
DNA quality (A260/280) 1.95 
Volume DNA Used (µl) 2.00 
Date GenePrint Solution expire 2015-06-22 
GenePrint Solution Used (µl) 10 
 
DNA Extraction: DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) 
DNA Quantification: Nanodrop ND1000 (Wilmington, DE) 
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2 Run Information 
Operator (CE) Sarah Low Hong Hui 
Run Date 2014-04-30 
Run File Name 20140430_cellID_sharonlow 
Run Loading Number A11 
 
Cell ID Analysis: Geneprint 10 system (Promega, Madison, WI) 
Capillary Electrophoresis: ABI 3130xl Genetic Analyser (Life Technologies, Foster City, 
CA) 
3 Run Results 
Locus Positive  LN229 
   
TH01 6, 9.3 9.3 
D21S11 29, 31.2 29,30 
D5S818 12, 12 11,12 
D13S317 9, 11 10,11 
D7S820 8, 11 8,11 
D16S539 9, 13 12 
CSF1PO 12, 12 12 
Amelogenin X, Y X 
vWA 16, 19 16,19 
TPOX 11, 11 8 
   
In Reference Database Yes Yes 
Closest Reference 2800M Control DNA LN229 
Reference Source Promega DSMZ 
Percent Match 100% 100% 
Percent Match Status Pass Pass 
Interpretation Run Passed Quality Control Cell line is LN229 
177 
 
   
 
Analysis: Gene mapper V4.0 software. (Life Technologies, Foster City, CA) 
Numbers indicate the allele designations for each locus. 
Electrophoragram is added below under Appendix for your reference 
Percent Match according to ICLAC Match Criteria Worksheet v1.1 
(http://standards.atcc.org) 
Designation of “Pass” Status is based on having a Percent Match of ≥80% to the 
Reference. 
4 References 
ANSI/ATCC ASN-0002-2011. Authentication of Human Cell Lines: Standardization of 




First number in the box represents the allele call that is reflected in the results table 
above. 













Sample: Positive Control (2800M) 
 
 
 
 
 
 
